{ "disease": "follicular-lymphoma", "label": "Follicular lymphoma", "url": "https://usebiotransfer.org/disease/follicular-lymphoma/", "built": "2026-09-12", "facts_hash": { "answers": "3060bd53728b", "targets": "539708995b64" }, "sources": { "targets": "Open Targets Platform GraphQL API v4", "trials": "ClinicalTrials.gov API v2" }, "retrieved": { "targets": "2026-09-12", "trials": "2026-09-12" }, "query": { "endpoint": "https://clinicaltrials.gov/api/v2/studies", "shape": "query.cond=&query.intr=&pageSize=200", "active_statuses": [ "ACTIVE_NOT_RECRUITING", "ENROLLING_BY_INVITATION", "NOT_YET_RECRUITING", "RECRUITING" ], "dedup": "by NCT id across synonyms", "study_types": "interventional counted in headline; observational reported separately", "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search" }, "targets": [ { "symbol": "BCL2", "ensembl": "ENSG00000171791", "n_drug_entries": 7, "n_distinct_drugs": 5, "drugs": { "APG-2575": "PHASE_3", "NAVITOCLAX": "APPROVAL", "OBATOCLAX": "PHASE_3", "OBLIMERSEN": "APPROVAL", "VENETOCLAX": "APPROVAL" }, "approved": [ "NAVITOCLAX", "OBLIMERSEN", "VENETOCLAX" ], "n_approved": 3, "approved_for": { "NAVITOCLAX": [], "OBLIMERSEN": [], "VENETOCLAX": [ "B-cell chronic lymphocytic leukemia" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "MS4A1", "ensembl": "ENSG00000156738", "n_drug_entries": 18, "n_distinct_drugs": 18, "drugs": { "EPCORITAMAB": "APPROVAL", "FBT-A05": "PHASE_1_2", "GLOFITAMAB": "APPROVAL", "LFB-R603": "PHASE_1", "MOSUNETUZUMAB": "APPROVAL", "MT-3724": "PHASE_2", "OBINUTUZUMAB": "APPROVAL", "OCARATUZUMAB": "PHASE_2", "OCRELIZUMAB": "APPROVAL", "ODRONEXTAMAB": "APPROVAL", "OFATUMUMAB": "APPROVAL", "RITUXIMAB": "APPROVAL", "TOSITUMOMAB": "APPROVAL", "TOSITUMOMAB 131I": "PHASE_3", "TRU-015": "PHASE_2", "UBLITUXIMAB": "APPROVAL", "VELTUZUMAB": "PHASE_2", "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN": "APPROVAL" }, "approved": [ "EPCORITAMAB", "GLOFITAMAB", "MOSUNETUZUMAB", "OBINUTUZUMAB", "OCRELIZUMAB", "ODRONEXTAMAB", "OFATUMUMAB", "RITUXIMAB", "TOSITUMOMAB", "UBLITUXIMAB", "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN" ], "n_approved": 11, "approved_for": { "EPCORITAMAB": [ "follicular lymphoma", "B-cell non-Hodgkin lymphoma", "diffuse large B-cell lymphoma" ], "GLOFITAMAB": [ "diffuse large B-cell lymphoma" ], "MOSUNETUZUMAB": [ "follicular lymphoma" ], "OBINUTUZUMAB": [ "follicular lymphoma", "B-cell chronic lymphocytic leukemia" ], "OCRELIZUMAB": [ "multiple sclerosis", "diffuse large B-cell lymphoma", "relapsing-remitting multiple sclerosis", "chronic progressive multiple sclerosis" ], "ODRONEXTAMAB": [ "follicular lymphoma" ], "OFATUMUMAB": [ "relapsing-remitting multiple sclerosis", "B-cell chronic lymphocytic leukemia", "multiple sclerosis", "secondary progressive multiple sclerosis" ], "RITUXIMAB": [ "non-Hodgkin lymphoma", "granulomatosis with polyangiitis", "B-cell chronic lymphocytic leukemia", "acute lymphoblastic leukemia", "rheumatoid arthritis", "microscopic polyangiitis", "pemphigus", "vasculitis" ], "TOSITUMOMAB": [ "non-Hodgkin lymphoma" ], "UBLITUXIMAB": [ "multiple sclerosis", "relapsing-remitting multiple sclerosis", "chronic progressive multiple sclerosis" ], "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN": [ "follicular lymphoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "CD19", "ensembl": "ENSG00000177455", "n_drug_entries": 14, "n_distinct_drugs": 14, "drugs": { "AXICABTAGENE CILOLEUCEL": "APPROVAL", "BLINATUMOMAB": "APPROVAL", "BREXUCABTAGENE AUTOLEUCEL": "APPROVAL", "COLTUXIMAB RAVTANSINE": "PHASE_2", "DENINTUZUMAB MAFODOTIN": "PHASE_2", "INEBILIZUMAB": "APPROVAL", "LISOCABTAGENE MARALEUCEL": "APPROVAL", "LONCASTUXIMAB TESIRINE": "APPROVAL", "MDX-1342": "PHASE_2", "OBECABTAGENE AUTOLEUCEL": "APPROVAL", "OBEXELIMAB": "PHASE_3", "ONCOLYSIN B": "PHASE_2", "TAFASITAMAB": "APPROVAL", "TISAGENLECLEUCEL": "APPROVAL" }, "approved": [ "AXICABTAGENE CILOLEUCEL", "BLINATUMOMAB", "BREXUCABTAGENE AUTOLEUCEL", "INEBILIZUMAB", "LISOCABTAGENE MARALEUCEL", "LONCASTUXIMAB TESIRINE", "OBECABTAGENE AUTOLEUCEL", "TAFASITAMAB", "TISAGENLECLEUCEL" ], "n_approved": 9, "approved_for": { "AXICABTAGENE CILOLEUCEL": [ "diffuse large B-cell lymphoma", "follicular lymphoma" ], "BLINATUMOMAB": [ "acute lymphoblastic leukemia", "B-cell acute lymphoblastic leukemia", "lymphoid leukemia" ], "BREXUCABTAGENE AUTOLEUCEL": [ "mantle cell lymphoma" ], "INEBILIZUMAB": [ "neuromyelitis optica" ], "LISOCABTAGENE MARALEUCEL": [ "diffuse large B-cell lymphoma", "follicular lymphoma", "neoplasm of mediastinum" ], "LONCASTUXIMAB TESIRINE": [ "diffuse large B-cell lymphoma", "B-cell neoplasm", "B-cell non-Hodgkin lymphoma" ], "OBECABTAGENE AUTOLEUCEL": [ "B-cell acute lymphoblastic leukemia" ], "TAFASITAMAB": [ "diffuse large B-cell lymphoma", "lymphoma" ], "TISAGENLECLEUCEL": [ "diffuse large B-cell lymphoma" ] }, "tractability": [ { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "EZH2", "ensembl": "ENSG00000106462", "n_drug_entries": 3, "n_distinct_drugs": 3, "drugs": { "GSK2816126": "PHASE_1", "TAZEMETOSTAT": "APPROVAL", "TAZEMETOSTAT HYDROBROMIDE": "APPROVAL" }, "approved": [ "TAZEMETOSTAT", "TAZEMETOSTAT HYDROBROMIDE" ], "n_approved": 2, "approved_for": { "TAZEMETOSTAT": [ "follicular lymphoma" ], "TAZEMETOSTAT HYDROBROMIDE": [ "follicular lymphoma", "sarcoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "CREBBP", "ensembl": "ENSG00000005339", "n_drug_entries": 1, "n_distinct_drugs": 1, "drugs": { "PRI-724": "PHASE_2" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "KMT2D", "ensembl": "ENSG00000167548", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] }, { "symbol": "CD79B", "ensembl": "ENSG00000007312", "n_drug_entries": 1, "n_distinct_drugs": 1, "drugs": { "POLATUZUMAB VEDOTIN": "APPROVAL" }, "approved": [ "POLATUZUMAB VEDOTIN" ], "n_approved": 1, "approved_for": { "POLATUZUMAB VEDOTIN": [ "diffuse large B-cell lymphoma", "B-cell non-Hodgkin lymphoma" ] }, "tractability": [ { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "PIK3CD", "ensembl": "ENSG00000171608", "n_drug_entries": 46, "n_distinct_drugs": 42, "drugs": { "ACALISIB": "PHASE_1", "AMG-319": "PHASE_2", "APITOLISIB": "PHASE_2", "AZD-6482": "UNKNOWN", "AZD-8186": "PHASE_1_2", "BGT-226": "PHASE_1_2", "BUPARLISIB": "PHASE_3", "CAL-263": "PHASE_1", "COPANLISIB": "APPROVAL", "DACTOLISIB": "PHASE_3", "DS-7423": "PHASE_1", "DUVELISIB": "APPROVAL", "FIMEPINOSTAT": "PHASE_2", "GEDATOLISIB": "PHASE_3", "GSK-1059615": "PHASE_1", "GSK-2269557": "PHASE_2", "IDELALISIB": "APPROVAL", "INCB-40093": "PHASE_2", "IZORLISIB": "PHASE_1_2", "LENIOLISIB": "APPROVAL", "NEMIRALISIB": "PHASE_2", "OMIPALISIB": "PHASE_1", "PANULISIB": "PHASE_1", "PARSACLISIB": "APPROVAL", "PAXALISIB": "PHASE_2_3", "PF-04691502": "PHASE_2", "PICTILISIB": "PHASE_2", "PILARALISIB": "PHASE_2", "RECILISIB": "PHASE_1", "SAMOTOLISIB": "PHASE_2", "SELETALISIB": "PHASE_2", "SF-1126": "PHASE_2", "SONOLISIB": "PHASE_2", "TASELISIB": "PHASE_3", "TENALISIB": "PHASE_2", "TG100-115": "PHASE_1_2", "UMBRALISIB": "APPROVAL", "VOXTALISIB": "PHASE_2", "VS-5584": "PHASE_1", "WX-037": "PHASE_1", "ZANDELISIB": "PHASE_3", "ZSTK-474": "PHASE_1" }, "approved": [ "COPANLISIB", "DUVELISIB", "IDELALISIB", "LENIOLISIB", "PARSACLISIB", "UMBRALISIB" ], "n_approved": 6, "approved_for": { "COPANLISIB": [ "follicular lymphoma", "non-Hodgkin lymphoma", "neoplasm of mature B-cells" ], "DUVELISIB": [ "follicular lymphoma", "B-cell chronic lymphocytic leukemia", "lymphoma", "neoplasm of mature B-cells" ], "IDELALISIB": [ "B-cell chronic lymphocytic leukemia", "neoplasm of mature B-cells", "non-Hodgkin lymphoma" ], "LENIOLISIB": [ "inborn error of immunity", "gastric cancer" ], "PARSACLISIB": [], "UMBRALISIB": [ "follicular lymphoma", "marginal zone lymphoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "BTK", "ensembl": "ENSG00000010671", "n_drug_entries": 24, "n_distinct_drugs": 20, "drugs": { "ABIVERTINIB": "PHASE_3", "ACALABRUTINIB": "APPROVAL", "BMS-986142": "PHASE_2", "BRANEBRUTINIB": "PHASE_2", "EDRALBRUTINIB": "PHASE_2", "ELSUBRUTINIB": "PHASE_2", "EVOBRUTINIB": "PHASE_3", "FENEBRUTINIB": "PHASE_3", "IBRUTINIB": "APPROVAL", "MSC-2364447": "PHASE_1", "ORELABRUTINIB": "APPROVAL", "PIRTOBRUTINIB": "APPROVAL", "POSELTINIB": "PHASE_2", "RILZABRUTINIB": "APPROVAL", "RITLECITINIB": "APPROVAL", "SPEBRUTINIB": "PHASE_2", "TIRABRUTINIB": "APPROVAL", "TOLEBRUTINIB": "PREAPPROVAL", "VECABRUTINIB": "PHASE_1_2", "ZANUBRUTINIB": "APPROVAL" }, "approved": [ "ACALABRUTINIB", "IBRUTINIB", "ORELABRUTINIB", "PIRTOBRUTINIB", "RILZABRUTINIB", "RITLECITINIB", "TIRABRUTINIB", "ZANUBRUTINIB" ], "n_approved": 8, "approved_for": { "ACALABRUTINIB": [ "B-cell chronic lymphocytic leukemia", "childhood leukemia", "mantle cell lymphoma" ], "IBRUTINIB": [ "macroglobulinemia", "mantle cell lymphoma", "B-cell chronic lymphocytic leukemia" ], "ORELABRUTINIB": [], "PIRTOBRUTINIB": [ "mantle cell lymphoma", "non-Hodgkin lymphoma" ], "RILZABRUTINIB": [ "autoimmune thrombocytopenic purpura" ], "RITLECITINIB": [ "alopecia areata" ], "TIRABRUTINIB": [], "ZANUBRUTINIB": [ "mantle cell lymphoma", "B-cell chronic lymphocytic leukemia", "lymphoplasmacytic lymphoma", "Waldenstrom macroglobulinemia" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Phase 1 Clinical" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "CD22", "ensembl": "ENSG00000012124", "n_drug_entries": 11, "n_distinct_drugs": 11, "drugs": { "BECTUMOMAB": "PHASE_3", "BL22": "PHASE_2", "EPRATUZUMAB": "PHASE_3", "EPRATUZUMAB-CYS-TESIRINE": "PHASE_1_2", "INOTUZUMAB": "PHASE_3", "INOTUZUMAB OZOGAMICIN": "APPROVAL", "MONO-DGA-RFB4": "PHASE_1", "MOXETUMOMAB PASUDOTOX": "APPROVAL", "PINATUZUMAB VEDOTIN": "PHASE_2", "YTTRIUM Y 90 EPRATUZUMAB": "PHASE_1_2", "YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN": "PHASE_2" }, "approved": [ "INOTUZUMAB OZOGAMICIN", "MOXETUMOMAB PASUDOTOX" ], "n_approved": 2, "approved_for": { "INOTUZUMAB OZOGAMICIN": [ "acute lymphoblastic leukemia", "B-cell acute lymphoblastic leukemia" ], "MOXETUMOMAB PASUDOTOX": [ "hairy cell leukemia" ] }, "tractability": [ { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "TNFRSF14", "ensembl": "ENSG00000157873", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" } ] }, { "symbol": "STAT6", "ensembl": "ENSG00000166888", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] } ], "trials": { "by_antigen": { "CD20": { "n": 385, "n_observational": 34, "n_active": 115, "n_withdrawn": 18, "trials": [ { "nct": "NCT02393157", "title": "Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL", "status": "RECRUITING", "last_update": "2025-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04110301", "title": "MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)", "status": "RECRUITING", "last_update": "2024-11-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04186520", "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies", "status": "RECRUITING", "last_update": "2026-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04792502", "title": "Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04830137", "title": "A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04834024", "title": "MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma", "status": "RECRUITING", "last_update": "2024-11-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04844866", "title": "Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients", "status": "RECRUITING", "last_update": "2026-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04883437", "title": "Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas", "status": "RECRUITING", "last_update": "2026-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04889716", "title": "CAR-T Followed by Bispecific Antibodies", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05045664", "title": "Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody", "status": "RECRUITING", "last_update": "2026-04-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05131022", "title": "A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05389293", "title": "A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05633615", "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma", "status": "RECRUITING", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05672251", "title": "Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05783609", "title": "Epcoritamab and Rituximab for First-line Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05826535", "title": "Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05848765", "title": "Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy", "status": "RECRUITING", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05849857", "title": "Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries", "status": "RECRUITING", "last_update": "2023-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05929222", "title": "Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06091254", "title": "A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06108232", "title": "Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06149286", "title": "A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06209619", "title": "CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06284122", "title": "Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5", "status": "RECRUITING", "last_update": "2026-06-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06287398", "title": "Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL", "status": "RECRUITING", "last_update": "2024-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06337318", "title": "Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06350318", "title": "Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas", "status": "RECRUITING", "last_update": "2026-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06442475", "title": "Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06453044", "title": "Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06471738", "title": "Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06510361", "title": "Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06536049", "title": "Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06542250", "title": "A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.", "status": "RECRUITING", "last_update": "2026-08-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06549595", "title": "A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06553352", "title": "Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma", "status": "RECRUITING", "last_update": "2024-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06563596", "title": "Epco, Zanu, Ritux for R/R FL or MZL", "status": "RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06703892", "title": "A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06784726", "title": "Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06792825", "title": "HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06806033", "title": "Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06854159", "title": "Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy", "status": "RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06905509", "title": "Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma", "status": "RECRUITING", "last_update": "2026-06-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06948786", "title": "Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06959732", "title": "Zanubrutinib Combined With G-CVP in Previously Untreated FL", "status": "RECRUITING", "last_update": "2025-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07126678", "title": "Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Na\u00efve Advanced Stage Follicular Lymphoma", "status": "RECRUITING", "last_update": "2025-08-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07128641", "title": "Odronextamab in Low Tumor Volume Advanced FL", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07191249", "title": "Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma .", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07197307", "title": "Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07226843", "title": "A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07299149", "title": "Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07418190", "title": "Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR\u00b2) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07548697", "title": "A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-04-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07555470", "title": "Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07634471", "title": "A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002663", "title": "Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies", "status": "COMPLETED", "last_update": "2023-02-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003280", "title": "Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma", "status": "COMPLETED", "last_update": "2019-05-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003356", "title": "Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma", "status": "COMPLETED", "last_update": "2013-10-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003397", "title": "Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2019-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003605", "title": "Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma", "status": "WITHDRAWN", "last_update": "2015-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003663", "title": "Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma", "status": "WITHDRAWN", "last_update": "2015-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003849", "title": "Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease", "status": "COMPLETED", "last_update": "2016-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003963", "title": "Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2020-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004031", "title": "SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2021-02-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004039", "title": "Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma", "status": "WITHDRAWN", "last_update": "2015-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004179", "title": "Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2021-02-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005592", "title": "Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2015-10-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005601", "title": "Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2016-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006669", "title": "Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma", "status": "WITHDRAWN", "last_update": "2021-10-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006721", "title": "S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2026-03-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00007852", "title": "Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2023-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00012051", "title": "Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2013-08-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00012207", "title": "Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2010-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00017381", "title": "Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2013-01-09", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00022971", "title": "Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2019-12-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00028717", "title": "Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma", "status": "UNKNOWN", "last_update": "2013-09-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00033423", "title": "Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2013-12-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00052936", "title": "Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2021-05-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00058227", "title": "Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma", "status": "COMPLETED", "last_update": "2013-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00060671", "title": "Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2015-01-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00062296", "title": "Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00069966", "title": "Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse", "status": "UNKNOWN", "last_update": "2009-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00071955", "title": "Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2013-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00072514", "title": "Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2017-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00073918", "title": "Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2017-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00073931", "title": "Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2015-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00077961", "title": "Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL", "status": "TERMINATED", "last_update": "2015-03-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00078598", "title": "A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma", "status": "UNKNOWN", "last_update": "2005-11-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00080886", "title": "Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2023-10-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00080925", "title": "T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies", "status": "COMPLETED", "last_update": "2012-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00089115", "title": "Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2013-08-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00092274", "title": "Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin\u00b4s Follicular Lymphoma", "status": "WITHDRAWN", "last_update": "2015-04-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00100737", "title": "Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)", "status": "TERMINATED", "last_update": "2006-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00110006", "title": "Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma", "status": "WITHDRAWN", "last_update": "2010-06-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00110071", "title": "Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2014-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00110149", "title": "Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2017-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00117975", "title": "Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2016-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00119392", "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2018-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00147121", "title": "Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)", "status": "COMPLETED", "last_update": "2016-09-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00168740", "title": "Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)", "status": "COMPLETED", "last_update": "2005-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00169208", "title": "Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2019-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00176475", "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease", "status": "TERMINATED", "last_update": "2013-09-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00182650", "title": "Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2009-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00183976", "title": "Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas", "status": "TERMINATED", "last_update": "2014-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00185393", "title": "Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy", "status": "COMPLETED", "last_update": "2008-12-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00193440", "title": "Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2010-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00238238", "title": "Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab", "status": "COMPLETED", "last_update": "2017-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00244855", "title": "Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2017-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00244946", "title": "Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2015-03-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00244985", "title": "Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2017-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00251394", "title": "Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma", "status": "COMPLETED", "last_update": "2010-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00258336", "title": "Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma", "status": "UNKNOWN", "last_update": "2014-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00265928", "title": "Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2008-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00278408", "title": "Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2025-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00278421", "title": "Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2021-03-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00288067", "title": "Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2014-10-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00290511", "title": "Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma", "status": "COMPLETED", "last_update": "2022-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00290667", "title": "Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma", "status": "COMPLETED", "last_update": "2021-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00295932", "title": "Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2018-11-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00299494", "title": "Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)", "status": "COMPLETED", "last_update": "2018-03-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00312845", "title": "Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2012-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00317096", "title": "FCM Versus R-FCM Followed by R-Maintenance or Observation Only", "status": "UNKNOWN", "last_update": "2021-05-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00334438", "title": "Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2016-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00354926", "title": "Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2016-01-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00363636", "title": "A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)", "status": "TERMINATED", "last_update": "2015-10-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00366275", "title": "Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma", "status": "COMPLETED", "last_update": "2012-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00384111", "title": "Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)", "status": "TERMINATED", "last_update": "2022-01-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00384150", "title": "Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)", "status": "TERMINATED", "last_update": "2015-11-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00387023", "title": "Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma", "status": "COMPLETED", "last_update": "2013-11-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00394836", "title": "HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab", "status": "COMPLETED", "last_update": "2014-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00397800", "title": "Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma", "status": "UNKNOWN", "last_update": "2012-08-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00398372", "title": "Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment", "status": "COMPLETED", "last_update": "2011-06-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00400478", "title": "A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13", "status": "COMPLETED", "last_update": "2016-05-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00400764", "title": "A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas", "status": "TERMINATED", "last_update": "2011-11-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00411086", "title": "Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma", "status": "COMPLETED", "last_update": "2017-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00428142", "title": "Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00430352", "title": "MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.", "status": "COMPLETED", "last_update": "2017-08-14", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00435955", "title": "Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma", "status": "UNKNOWN", "last_update": "2007-02-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00438880", "title": "Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2016-02-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00452127", "title": "A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2013-01-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00460109", "title": "Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2017-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00493454", "title": "Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas", "status": "TERMINATED", "last_update": "2013-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00494780", "title": "Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients", "status": "COMPLETED", "last_update": "2014-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00496873", "title": "Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan", "status": "COMPLETED", "last_update": "2023-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00509379", "title": "Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma", "status": "COMPLETED", "last_update": "2011-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00510887", "title": "Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma", "status": "TERMINATED", "last_update": "2014-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00517049", "title": "A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)", "status": "COMPLETED", "last_update": "2017-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00521261", "title": "Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "WITHDRAWN", "last_update": "2014-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00536978", "title": "Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2020-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00546377", "title": "Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer", "status": "COMPLETED", "last_update": "2016-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00546793", "title": "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL", "status": "COMPLETED", "last_update": "2021-08-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00551239", "title": "Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma", "status": "WITHDRAWN", "last_update": "2020-10-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00553501", "title": "Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2016-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00556699", "title": "A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2014-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00561756", "title": "Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma", "status": "COMPLETED", "last_update": "2015-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00562978", "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients", "status": "COMPLETED", "last_update": "2021-06-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00574730", "title": "CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2023-09-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00577993", "title": "Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients", "status": "COMPLETED", "last_update": "2020-11-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00596804", "title": "Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2021-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00601718", "title": "Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma", "status": "COMPLETED", "last_update": "2017-05-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00617929", "title": "Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant", "status": "TERMINATED", "last_update": "2017-12-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00621452", "title": "Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2014-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00625729", "title": "Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2017-12-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00634179", "title": "A Phase I/II Trial of VR-CHOP in Lymphoma Patients", "status": "COMPLETED", "last_update": "2016-10-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00691652", "title": "Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2019-11-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00695409", "title": "Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2018-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00695786", "title": "Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2021-10-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00715208", "title": "Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma", "status": "COMPLETED", "last_update": "2013-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00719472", "title": "A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)", "status": "COMPLETED", "last_update": "2017-05-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00720135", "title": "Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2015-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00742144", "title": "Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2017-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00772668", "title": "Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL", "status": "TERMINATED", "last_update": "2017-12-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00783367", "title": "Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas", "status": "COMPLETED", "last_update": "2023-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00818961", "title": "Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer", "status": "TERMINATED", "last_update": "2013-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00825149", "title": "A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2016-11-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00842114", "title": "Rituximab and CVP Plus Interferon for Follicular Non Hodgkins Lymphoma (NHL)", "status": "COMPLETED", "last_update": "2016-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00859001", "title": "Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy", "status": "COMPLETED", "last_update": "2009-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00867529", "title": "Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma", "status": "COMPLETED", "last_update": "2018-01-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00880815", "title": "Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant", "status": "COMPLETED", "last_update": "2019-06-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00896519", "title": "GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma", "status": "UNKNOWN", "last_update": "2013-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00904722", "title": "Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma", "status": "COMPLETED", "last_update": "2016-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00912223", "title": "Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)", "status": "COMPLETED", "last_update": "2022-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00968760", "title": "CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2023-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00987493", "title": "Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma", "status": "COMPLETED", "last_update": "2019-05-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00989586", "title": "Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2017-02-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00991211", "title": "Bendamustine Plus Rituximab Versus CHOP Plus Rituximab", "status": "COMPLETED", "last_update": "2024-08-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00992446", "title": "Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2020-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01044745", "title": "Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer", "status": "TERMINATED", "last_update": "2023-09-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01059630", "title": "A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)", "status": "COMPLETED", "last_update": "2020-01-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01077518", "title": "Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy", "status": "TERMINATED", "last_update": "2020-03-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01116232", "title": "Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation", "status": "TERMINATED", "last_update": "2019-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01124526", "title": "Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma", "status": "COMPLETED", "last_update": "2010-05-17", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01127841", "title": "Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line", "status": "UNKNOWN", "last_update": "2013-08-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01145495", "title": "Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2023-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01147393", "title": "Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma", "status": "TERMINATED", "last_update": "2018-02-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01186458", "title": "Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2016-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01193842", "title": "Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas", "status": "COMPLETED", "last_update": "2023-11-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01200758", "title": "A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2018-11-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01210287", "title": "Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP", "status": "UNKNOWN", "last_update": "2014-01-08", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01216683", "title": "Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma", "status": "COMPLETED", "last_update": "2023-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01238146", "title": "Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma", "status": "WITHDRAWN", "last_update": "2013-06-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01239394", "title": "Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma", "status": "COMPLETED", "last_update": "2017-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01275209", "title": "Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma", "status": "COMPLETED", "last_update": "2020-12-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01307592", "title": "Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma", "status": "UNKNOWN", "last_update": "2014-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01307605", "title": "Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01318317", "title": "Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01326702", "title": "Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors", "status": "COMPLETED", "last_update": "2019-12-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01329354", "title": "Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy", "status": "UNKNOWN", "last_update": "2017-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01361191", "title": "Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma", "status": "COMPLETED", "last_update": "2013-10-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01370694", "title": "Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)", "status": "TERMINATED", "last_update": "2019-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01381692", "title": "Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma", "status": "COMPLETED", "last_update": "2021-10-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01397591", "title": "Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma", "status": "TERMINATED", "last_update": "2014-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01419665", "title": "GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)", "status": "COMPLETED", "last_update": "2021-05-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01419795", "title": "Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant", "status": "TERMINATED", "last_update": "2017-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01446562", "title": "Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma", "status": "COMPLETED", "last_update": "2016-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01460602", "title": "Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma", "status": "WITHDRAWN", "last_update": "2020-09-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01473628", "title": "Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01493479", "title": "Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma", "status": "COMPLETED", "last_update": "2019-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01510184", "title": "Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy", "status": "TERMINATED", "last_update": "2021-12-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01560117", "title": "Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma", "status": "COMPLETED", "last_update": "2018-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01569750", "title": "A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2017-08-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01582776", "title": "Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma", "status": "COMPLETED", "last_update": "2023-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01680991", "title": "A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease", "status": "COMPLETED", "last_update": "2016-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01682044", "title": "Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma", "status": "COMPLETED", "last_update": "2017-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01691898", "title": "A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)", "status": "COMPLETED", "last_update": "2020-02-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01701232", "title": "Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2017-11-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01724021", "title": "A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a", "status": "COMPLETED", "last_update": "2018-01-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01735604", "title": "Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy", "status": "UNKNOWN", "last_update": "2015-09-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01796171", "title": "A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2024-06-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01830465", "title": "VELCADE\u00ae Plus Rituximab in Non Hodgkin's Follicular Lymphoma", "status": "COMPLETED", "last_update": "2013-04-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01852435", "title": "R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B", "status": "UNKNOWN", "last_update": "2017-11-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01987505", "title": "MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma", "status": "COMPLETED", "last_update": "2018-12-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01994382", "title": "Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL", "status": "COMPLETED", "last_update": "2022-04-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01995669", "title": "Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2025-06-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02049541", "title": "Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02063685", "title": "Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma", "status": "COMPLETED", "last_update": "2022-06-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02162771", "title": "To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan", "status": "COMPLETED", "last_update": "2020-01-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02168907", "title": "CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2018-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213263", "title": "A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera\u00ae (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)", "status": "COMPLETED", "last_update": "2019-06-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02220842", "title": "A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma", "status": "COMPLETED", "last_update": "2020-01-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02257567", "title": "A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma", "status": "COMPLETED", "last_update": "2022-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02258529", "title": "Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2019-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02260804", "title": "To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02290951", "title": "Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies", "status": "COMPLETED", "last_update": "2025-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02303119", "title": "Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)", "status": "COMPLETED", "last_update": "2023-01-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02320292", "title": "Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma", "status": "TERMINATED", "last_update": "2025-07-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02339922", "title": "Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02348216", "title": "Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2024-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02384954", "title": "QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab", "status": "TERMINATED", "last_update": "2024-07-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02390869", "title": "Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02391545", "title": "A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)", "status": "TERMINATED", "last_update": "2023-09-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02406092", "title": "Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A", "status": "COMPLETED", "last_update": "2024-11-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02423837", "title": "Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma", "status": "UNKNOWN", "last_update": "2015-04-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02446457", "title": "Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02499003", "title": "GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma", "status": "COMPLETED", "last_update": "2022-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02501473", "title": "Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)", "status": "TERMINATED", "last_update": "2020-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02532257", "title": "Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma", "status": "COMPLETED", "last_update": "2024-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02541565", "title": "Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma", "status": "COMPLETED", "last_update": "2020-10-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02594163", "title": "Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma", "status": "TERMINATED", "last_update": "2018-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02596971", "title": "A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)", "status": "COMPLETED", "last_update": "2021-05-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02600897", "title": "A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "status": "COMPLETED", "last_update": "2023-12-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02611323", "title": "A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)", "status": "COMPLETED", "last_update": "2023-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02623920", "title": "Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "status": "WITHDRAWN", "last_update": "2017-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02624986", "title": "A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants", "status": "TERMINATED", "last_update": "2020-05-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02631577", "title": "A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma", "status": "COMPLETED", "last_update": "2022-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02657447", "title": "Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)", "status": "WITHDRAWN", "last_update": "2019-01-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02689869", "title": "Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma", "status": "UNKNOWN", "last_update": "2021-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02700022", "title": "A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas", "status": "TERMINATED", "last_update": "2017-11-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02729896", "title": "A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "status": "COMPLETED", "last_update": "2020-12-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02855359", "title": "Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma", "status": "TERMINATED", "last_update": "2019-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02871219", "title": "Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma", "status": "COMPLETED", "last_update": "2025-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02877550", "title": "Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients", "status": "COMPLETED", "last_update": "2022-06-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02889523", "title": "Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02924402", "title": "Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies", "status": "COMPLETED", "last_update": "2024-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983097", "title": "Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP", "status": "TERMINATED", "last_update": "2018-01-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02992522", "title": "Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03003546", "title": "Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial", "status": "COMPLETED", "last_update": "2023-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03010358", "title": "Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2023-08-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03019640", "title": "Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2023-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03019666", "title": "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL", "status": "COMPLETED", "last_update": "2022-11-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03039114", "title": "Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)", "status": "COMPLETED", "last_update": "2025-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03057418", "title": "Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auri\u0445im", "status": "COMPLETED", "last_update": "2017-05-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03069248", "title": "Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon", "status": "COMPLETED", "last_update": "2017-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03097770", "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20", "status": "COMPLETED", "last_update": "2020-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03113422", "title": "Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy", "status": "COMPLETED", "last_update": "2025-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03121677", "title": "Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03135262", "title": "A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)", "status": "TERMINATED", "last_update": "2021-12-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03198026", "title": "Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03221348", "title": "A Phase I Study of Intravenous CHO-H01 in Patients With Refractory or Relapsed Follicular Lymphoma", "status": "UNKNOWN", "last_update": "2018-01-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03269669", "title": "Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03276468", "title": "Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas", "status": "COMPLETED", "last_update": "2023-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03277729", "title": "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03321643", "title": "Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03332017", "title": "A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma", "status": "COMPLETED", "last_update": "2026-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03341520", "title": "Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma", "status": "COMPLETED", "last_update": "2026-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03361852", "title": "Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03401853", "title": "Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma", "status": "TERMINATED", "last_update": "2025-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03424122", "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)", "status": "COMPLETED", "last_update": "2025-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03440567", "title": "Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma", "status": "COMPLETED", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03492775", "title": "First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients \u2265 60 Years", "status": "COMPLETED", "last_update": "2023-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03579927", "title": "CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma", "status": "WITHDRAWN", "last_update": "2020-01-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03636503", "title": "Rituximab + Immunotherapy in Follicular Lymphoma", "status": "TERMINATED", "last_update": "2025-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03704714", "title": "Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma", "status": "SUSPENDED", "last_update": "2022-08-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03789240", "title": "Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03806179", "title": "Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL", "status": "COMPLETED", "last_update": "2023-12-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03817853", "title": "An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma", "status": "COMPLETED", "last_update": "2024-04-04", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03828448", "title": "Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Na\u00efve Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03888105", "title": "A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03890289", "title": "Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma", "status": "TERMINATED", "last_update": "2024-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03919175", "title": "Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma", "status": "TERMINATED", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03976102", "title": "Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera\u00ae in LTB Follicular Lymphoma", "status": "COMPLETED", "last_update": "2024-01-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03980171", "title": "Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Na\u00efve Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04007029", "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04138875", "title": "A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)", "status": "WITHDRAWN", "last_update": "2022-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04176913", "title": "Study of LUCAR-20S in Patients With R/R NHL", "status": "TERMINATED", "last_update": "2022-01-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04224493", "title": "A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04246086", "title": "A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04323956", "title": "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04358458", "title": "First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas", "status": "TERMINATED", "last_update": "2024-10-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04404088", "title": "Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04447716", "title": "An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04450173", "title": "Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04542824", "title": "Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04578600", "title": "CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma", "status": "COMPLETED", "last_update": "2025-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04599634", "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies", "status": "COMPLETED", "last_update": "2025-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04628494", "title": "A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04659044", "title": "Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma", "status": "TERMINATED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04663347", "title": "Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04680052", "title": "A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04712097", "title": "A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04722601", "title": "A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma", "status": "TERMINATED", "last_update": "2024-05-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04735471", "title": "A Phase 1 Study of ADI-001 in B Cell Malignancies", "status": "TERMINATED", "last_update": "2025-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04745832", "title": "Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)", "status": "TERMINATED", "last_update": "2024-11-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762160", "title": "SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma", "status": "TERMINATED", "last_update": "2024-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04796922", "title": "To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)", "status": "WITHDRAWN", "last_update": "2022-07-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04799275", "title": "Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04806035", "title": "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2024-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04850495", "title": "Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04918940", "title": "Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma", "status": "COMPLETED", "last_update": "2022-12-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04934930", "title": "Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status", "status": "UNKNOWN", "last_update": "2021-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04962126", "title": "Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05003141", "title": "PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies", "status": "UNKNOWN", "last_update": "2022-03-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05025800", "title": "ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05058404", "title": "Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05073250", "title": "IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.", "status": "UNKNOWN", "last_update": "2023-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05100862", "title": "A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05169489", "title": "A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)", "status": "TERMINATED", "last_update": "2025-10-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05169658", "title": "Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05315713", "title": "An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2024-10-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05360238", "title": "Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL", "status": "TERMINATED", "last_update": "2024-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05387616", "title": "A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden", "status": "UNKNOWN", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05409066", "title": "Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05410418", "title": "Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05412290", "title": "Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05451810", "title": "A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05455697", "title": "Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05464329", "title": "Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05653271", "title": "ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies", "status": "COMPLETED", "last_update": "2026-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05660967", "title": "Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma", "status": "TERMINATED", "last_update": "2026-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05783596", "title": "Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05867030", "title": "Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma", "status": "WITHDRAWN", "last_update": "2023-10-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05888493", "title": "A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05950165", "title": "A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05994235", "title": "Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06097364", "title": "A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06112847", "title": "Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06191744", "title": "Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06313996", "title": "A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma", "status": "WITHDRAWN", "last_update": "2026-03-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06474481", "title": "Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06492837", "title": "Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06549335", "title": "Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06575686", "title": "Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma", "status": "SUSPENDED", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06918015", "title": "Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06961500", "title": "Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07024147", "title": "JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07030699", "title": "A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma", "status": "WITHDRAWN", "last_update": "2026-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07031700", "title": "A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07187960", "title": "Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07505849", "title": "ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07714421", "title": "Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07719855", "title": "A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07731789", "title": "Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07736950", "title": "A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07783594", "title": "Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07814001", "title": "Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 22, "n_observational": 2, "n_active": 12, "n_withdrawn": 2, "trials": [ { "nct": "NCT04186520", "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies", "status": "RECRUITING", "last_update": "2026-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04844866", "title": "Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients", "status": "RECRUITING", "last_update": "2026-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04889716", "title": "CAR-T Followed by Bispecific Antibodies", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05633615", "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma", "status": "RECRUITING", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06209619", "title": "CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06703892", "title": "A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06784726", "title": "Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06854159", "title": "Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy", "status": "RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00176475", "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease", "status": "TERMINATED", "last_update": "2013-09-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00182650", "title": "Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2009-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00521261", "title": "Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "WITHDRAWN", "last_update": "2014-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00621452", "title": "Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2014-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01318317", "title": "Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01329354", "title": "Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy", "status": "UNKNOWN", "last_update": "2017-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01735604", "title": "Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy", "status": "UNKNOWN", "last_update": "2015-09-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03019640", "title": "Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2023-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03019666", "title": "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL", "status": "COMPLETED", "last_update": "2022-11-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03097770", "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20", "status": "COMPLETED", "last_update": "2020-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03277729", "title": "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03579927", "title": "CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma", "status": "WITHDRAWN", "last_update": "2020-01-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04007029", "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07814001", "title": "Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "CD20", "MS4A1", "rituximab", "obinutuzumab", "mosunetuzumab", "Lunsumio", "epcoritamab", "odronextamab" ] }, "CD19": { "n": 120, "n_observational": 9, "n_active": 63, "n_withdrawn": 5, "trials": [ { "nct": "NCT03676504", "title": "Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR", "status": "RECRUITING", "last_update": "2024-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04186520", "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies", "status": "RECRUITING", "last_update": "2026-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04545762", "title": "Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04830137", "title": "A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04836507", "title": "Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients", "status": "RECRUITING", "last_update": "2026-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04844866", "title": "Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients", "status": "RECRUITING", "last_update": "2026-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04889716", "title": "CAR-T Followed by Bispecific Antibodies", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05077527", "title": "Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05281809", "title": "Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia", "status": "RECRUITING", "last_update": "2025-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05326243", "title": "Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma", "status": "RECRUITING", "last_update": "2025-05-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05365659", "title": "IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05633615", "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma", "status": "RECRUITING", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05643742", "title": "A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies", "status": "RECRUITING", "last_update": "2025-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05672251", "title": "Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05826535", "title": "Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05890352", "title": "Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment", "status": "RECRUITING", "last_update": "2025-10-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06026319", "title": "CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-03-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06043323", "title": "A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06045910", "title": "A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies", "status": "RECRUITING", "last_update": "2025-07-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06213636", "title": "Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).", "status": "RECRUITING", "last_update": "2025-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06533579", "title": "Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06544265", "title": "SynKIR-310 for Relapsed/Refractory B-NHL", "status": "RECRUITING", "last_update": "2026-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06550141", "title": "Emapalumab Prevention of CAR-T Cell Associated Toxicities", "status": "RECRUITING", "last_update": "2025-11-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06792825", "title": "HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06826118", "title": "Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma", "status": "RECRUITING", "last_update": "2025-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06830031", "title": "Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07042438", "title": "Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07077512", "title": "Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07225439", "title": "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07343934", "title": "huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07473167", "title": "Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients", "status": "RECRUITING", "last_update": "2026-03-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07502118", "title": "NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07548697", "title": "A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-04-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07587840", "title": "CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07788118", "title": "A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7\u00d719-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003874", "title": "Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia", "status": "COMPLETED", "last_update": "2011-11-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00182650", "title": "Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2009-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00816413", "title": "Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer", "status": "WITHDRAWN", "last_update": "2023-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00889408", "title": "DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma", "status": "COMPLETED", "last_update": "2017-12-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00924326", "title": "CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma", "status": "COMPLETED", "last_update": "2022-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00968760", "title": "CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2023-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00989586", "title": "Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2017-02-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01029366", "title": "CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy", "status": "COMPLETED", "last_update": "2023-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01318317", "title": "Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01497184", "title": "Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood", "status": "COMPLETED", "last_update": "2025-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01786135", "title": "A Safety Study of SGN-CD19A for B-Cell Lymphoma", "status": "COMPLETED", "last_update": "2017-10-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01815749", "title": "Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01864889", "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19", "status": "UNKNOWN", "last_update": "2016-01-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02134262", "title": "Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes", "status": "UNKNOWN", "last_update": "2014-11-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02153580", "title": "Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02274506", "title": "Infusion of Allogeneic, 3rd Party CD19-specific T Cells", "status": "WITHDRAWN", "last_update": "2020-01-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02348216", "title": "Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2024-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02454270", "title": "A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies", "status": "TERMINATED", "last_update": "2018-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02568553", "title": "Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2025-11-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02592876", "title": "Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma", "status": "TERMINATED", "last_update": "2019-05-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02631044", "title": "Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)", "status": "COMPLETED", "last_update": "2024-06-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02650999", "title": "Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas", "status": "COMPLETED", "last_update": "2021-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02652910", "title": "Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma", "status": "UNKNOWN", "last_update": "2019-02-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02685670", "title": "Competitive Transfer of \u03b1CD19-TCRz-CD28 and \u03b1CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma", "status": "UNKNOWN", "last_update": "2017-03-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02702141", "title": "A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2018-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02721407", "title": "Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients", "status": "UNKNOWN", "last_update": "2017-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02819583", "title": "CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2016-10-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02851589", "title": "Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2016-08-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02855359", "title": "Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma", "status": "TERMINATED", "last_update": "2019-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02892695", "title": "PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2016-12-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03097770", "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20", "status": "COMPLETED", "last_update": "2020-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03105336", "title": "A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2025-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03185494", "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22", "status": "UNKNOWN", "last_update": "2019-04-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03484702", "title": "Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2024-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03568461", "title": "Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma", "status": "COMPLETED", "last_update": "2026-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03570892", "title": "Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2026-06-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03571828", "title": "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma", "status": "TERMINATED", "last_update": "2024-03-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03610724", "title": "Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients", "status": "COMPLETED", "last_update": "2024-06-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03720457", "title": "Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.", "status": "UNKNOWN", "last_update": "2021-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03939026", "title": "Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma", "status": "COMPLETED", "last_update": "2026-03-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04007029", "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04049513", "title": "ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04089215", "title": "CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma", "status": "UNKNOWN", "last_update": "2023-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04184414", "title": "The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies", "status": "UNKNOWN", "last_update": "2019-12-03", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04205838", "title": "Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma", "status": "TERMINATED", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04257578", "title": "Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04432506", "title": "Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma", "status": "COMPLETED", "last_update": "2025-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04450069", "title": "CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies", "status": "COMPLETED", "last_update": "2024-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464200", "title": "19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04488354", "title": "Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T", "status": "COMPLETED", "last_update": "2026-04-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04594642", "title": "A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04680052", "title": "A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04745559", "title": "Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04806035", "title": "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2024-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04844086", "title": "RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies", "status": "TERMINATED", "last_update": "2022-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04855253", "title": "Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL", "status": "SUSPENDED", "last_update": "2026-01-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05020392", "title": "Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma", "status": "UNKNOWN", "last_update": "2023-07-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05075603", "title": "Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy", "status": "COMPLETED", "last_update": "2026-08-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05228249", "title": "Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma", "status": "WITHDRAWN", "last_update": "2023-01-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05336409", "title": "A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies", "status": "TERMINATED", "last_update": "2025-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05359211", "title": "NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05371093", "title": "Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05453396", "title": "Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies", "status": "TERMINATED", "last_update": "2026-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05455697", "title": "Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05583149", "title": "Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05621096", "title": "Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05665062", "title": "Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05821088", "title": "Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05878184", "title": "Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05888493", "title": "A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06093841", "title": "Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06256484", "title": "A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2026-03-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06313996", "title": "A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma", "status": "WITHDRAWN", "last_update": "2026-03-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06343376", "title": "Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies", "status": "TERMINATED", "last_update": "2025-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06561425", "title": "A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2026-06-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07024147", "title": "JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07030699", "title": "A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma", "status": "WITHDRAWN", "last_update": "2026-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07098364", "title": "ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma", "status": "SUSPENDED", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07168291", "title": "Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-17", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07360288", "title": "Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07412405", "title": "This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07503353", "title": "A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07585747", "title": "A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07713459", "title": "A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07731789", "title": "Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 57, "n_observational": 4, "n_active": 30, "n_withdrawn": 1, "trials": [ { "nct": "NCT03676504", "title": "Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR", "status": "RECRUITING", "last_update": "2024-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04186520", "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies", "status": "RECRUITING", "last_update": "2026-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04545762", "title": "Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04844866", "title": "Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients", "status": "RECRUITING", "last_update": "2026-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04889716", "title": "CAR-T Followed by Bispecific Antibodies", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05077527", "title": "Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05281809", "title": "Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia", "status": "RECRUITING", "last_update": "2025-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05326243", "title": "Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma", "status": "RECRUITING", "last_update": "2025-05-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05633615", "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma", "status": "RECRUITING", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06026319", "title": "CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-03-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06043323", "title": "A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06213636", "title": "Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).", "status": "RECRUITING", "last_update": "2025-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06550141", "title": "Emapalumab Prevention of CAR-T Cell Associated Toxicities", "status": "RECRUITING", "last_update": "2025-11-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06830031", "title": "Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07042438", "title": "Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07225439", "title": "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07343934", "title": "huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07587840", "title": "CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07788118", "title": "A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7\u00d719-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00182650", "title": "Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2009-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00924326", "title": "CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma", "status": "COMPLETED", "last_update": "2022-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01029366", "title": "CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy", "status": "COMPLETED", "last_update": "2023-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01318317", "title": "Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01497184", "title": "Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood", "status": "COMPLETED", "last_update": "2025-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01864889", "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19", "status": "UNKNOWN", "last_update": "2016-01-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02134262", "title": "Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes", "status": "UNKNOWN", "last_update": "2014-11-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02153580", "title": "Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02274506", "title": "Infusion of Allogeneic, 3rd Party CD19-specific T Cells", "status": "WITHDRAWN", "last_update": "2020-01-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02650999", "title": "Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas", "status": "COMPLETED", "last_update": "2021-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02652910", "title": "Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma", "status": "UNKNOWN", "last_update": "2019-02-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02685670", "title": "Competitive Transfer of \u03b1CD19-TCRz-CD28 and \u03b1CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma", "status": "UNKNOWN", "last_update": "2017-03-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02721407", "title": "Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients", "status": "UNKNOWN", "last_update": "2017-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02819583", "title": "CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2016-10-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03097770", "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20", "status": "COMPLETED", "last_update": "2020-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03185494", "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22", "status": "UNKNOWN", "last_update": "2019-04-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03720457", "title": "Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.", "status": "UNKNOWN", "last_update": "2021-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03939026", "title": "Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma", "status": "COMPLETED", "last_update": "2026-03-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04007029", "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04049513", "title": "ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04089215", "title": "CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma", "status": "UNKNOWN", "last_update": "2023-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04184414", "title": "The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies", "status": "UNKNOWN", "last_update": "2019-12-03", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04205838", "title": "Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma", "status": "TERMINATED", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04257578", "title": "Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04432506", "title": "Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma", "status": "COMPLETED", "last_update": "2025-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464200", "title": "19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04488354", "title": "Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T", "status": "COMPLETED", "last_update": "2026-04-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04745559", "title": "Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04844086", "title": "RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies", "status": "TERMINATED", "last_update": "2022-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04855253", "title": "Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL", "status": "SUSPENDED", "last_update": "2026-01-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05020392", "title": "Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma", "status": "UNKNOWN", "last_update": "2023-07-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05075603", "title": "Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy", "status": "COMPLETED", "last_update": "2026-08-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05359211", "title": "NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05665062", "title": "Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06343376", "title": "Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies", "status": "TERMINATED", "last_update": "2025-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07098364", "title": "ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma", "status": "SUSPENDED", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07168291", "title": "Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-17", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07412405", "title": "This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-17", "phase": "NA", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "CD19", "axicabtagene", "axi-cel", "Yescarta", "tisagenlecleucel", "Kymriah", "lisocabtagene", "tafasitamab" ] }, "BCL-2": { "n": 42, "n_observational": 2, "n_active": 14, "n_withdrawn": 0, "trials": [ { "nct": "NCT05131022", "title": "A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06471738", "title": "Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06806033", "title": "Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06859008", "title": "Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-04-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07609862", "title": "A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00001572", "title": "Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype", "status": "COMPLETED", "last_update": "2017-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00054639", "title": "Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2014-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00060112", "title": "Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma", "status": "TERMINATED", "last_update": "2013-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00086944", "title": "Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2013-01-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00301795", "title": "Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2013-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00366275", "title": "Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma", "status": "COMPLETED", "last_update": "2012-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00772655", "title": "Zevalin\u00ae First Line in Follicular Lymphoma", "status": "UNKNOWN", "last_update": "2012-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02187861", "title": "A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)", "status": "COMPLETED", "last_update": "2019-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02611323", "title": "A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)", "status": "COMPLETED", "last_update": "2023-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02710643", "title": "\"MIRO\" Molecularly Oriented Immuno-radio-therapy", "status": "COMPLETED", "last_update": "2022-06-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02877550", "title": "Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients", "status": "COMPLETED", "last_update": "2022-06-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02956382", "title": "Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma", "status": "COMPLETED", "last_update": "2025-07-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02992522", "title": "Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03113422", "title": "Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy", "status": "COMPLETED", "last_update": "2025-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03132584", "title": "Cyclophosphamide and Alemtuzumab In Lymphoma", "status": "TERMINATED", "last_update": "2019-01-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03135262", "title": "A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)", "status": "TERMINATED", "last_update": "2021-12-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03162536", "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03276468", "title": "Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas", "status": "COMPLETED", "last_update": "2023-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03357627", "title": "A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2023-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03547115", "title": "A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML", "status": "TERMINATED", "last_update": "2026-03-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03552692", "title": "Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma", "status": "TERMINATED", "last_update": "2023-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03583424", "title": "Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2025-05-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03886649", "title": "Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.", "status": "TERMINATED", "last_update": "2022-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03980171", "title": "Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Na\u00efve Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04072458", "title": "A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04447716", "title": "An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04450173", "title": "Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04599634", "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies", "status": "COMPLETED", "last_update": "2025-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04659044", "title": "Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma", "status": "TERMINATED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04722601", "title": "A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma", "status": "TERMINATED", "last_update": "2024-05-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04799275", "title": "Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05107856", "title": "PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies", "status": "TERMINATED", "last_update": "2024-01-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05583149", "title": "Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05618366", "title": "Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2026-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05753501", "title": "Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05828589", "title": "A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies", "status": "TERMINATED", "last_update": "2026-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "BCL-2", "venetoclax" ] }, "EZH2": { "n": 22, "n_observational": 3, "n_active": 9, "n_withdrawn": 3, "trials": [ { "nct": "NCT03460977", "title": "A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05890352", "title": "Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment", "status": "RECRUITING", "last_update": "2025-10-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07545603", "title": "Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01897571", "title": "Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL", "status": "COMPLETED", "last_update": "2024-03-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02220842", "title": "A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma", "status": "COMPLETED", "last_update": "2020-01-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02875548", "title": "A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study", "status": "COMPLETED", "last_update": "2025-11-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02889523", "title": "Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03010982", "title": "Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors", "status": "COMPLETED", "last_update": "2024-03-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03456726", "title": "Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation", "status": "COMPLETED", "last_update": "2022-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04224493", "title": "A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04537715", "title": "Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels", "status": "COMPLETED", "last_update": "2025-02-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762160", "title": "SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma", "status": "TERMINATED", "last_update": "2024-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05152459", "title": "Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma", "status": "WITHDRAWN", "last_update": "2023-05-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05467943", "title": "Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma", "status": "COMPLETED", "last_update": "2025-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05551936", "title": "A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05604417", "title": "Zandelisib + Tazemetostat in R/R Follicular Lymphoma", "status": "WITHDRAWN", "last_update": "2023-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05618366", "title": "Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2026-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05627245", "title": "Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05934838", "title": "A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05994235", "title": "Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06068881", "title": "A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an \"EZH2 Gain-of-function\" Genetic Mutation", "status": "WITHDRAWN", "last_update": "2026-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06575686", "title": "Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma", "status": "SUSPENDED", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05934838", "title": "A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "EZH2", "tazemetostat", "Tazverik" ] }, "PI3K": { "n": 57, "n_observational": 3, "n_active": 6, "n_withdrawn": 6, "trials": [ { "nct": "NCT04803201", "title": "Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06522737", "title": "A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07293403", "title": "Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01282424", "title": "Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas", "status": "COMPLETED", "last_update": "2019-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01306643", "title": "Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma", "status": "COMPLETED", "last_update": "2018-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01644799", "title": "Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma", "status": "COMPLETED", "last_update": "2026-06-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01693614", "title": "Safety and Efficacy of BKM120 in Relapsed and Refractory NHL", "status": "COMPLETED", "last_update": "2018-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01719250", "title": "Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2018-10-09", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01732913", "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas", "status": "TERMINATED", "last_update": "2018-11-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01732926", "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas", "status": "TERMINATED", "last_update": "2018-11-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01799889", "title": "Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies", "status": "TERMINATED", "last_update": "2020-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02049541", "title": "Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02204982", "title": "Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-09-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02242045", "title": "Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2021-03-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02258529", "title": "Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2019-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02258555", "title": "Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2015-10-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02332980", "title": "Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas", "status": "COMPLETED", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02391545", "title": "A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)", "status": "TERMINATED", "last_update": "2023-09-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02536300", "title": "Dose Optimization Study of Idelalisib in Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02576275", "title": "A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)", "status": "WITHDRAWN", "last_update": "2021-03-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02603445", "title": "Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL", "status": "COMPLETED", "last_update": "2020-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02605694", "title": "Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)", "status": "WITHDRAWN", "last_update": "2021-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02793583", "title": "Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma", "status": "TERMINATED", "last_update": "2022-07-21", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03039114", "title": "Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)", "status": "COMPLETED", "last_update": "2025-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126019", "title": "A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma", "status": "COMPLETED", "last_update": "2025-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03133221", "title": "1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2025-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03151057", "title": "Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies", "status": "TERMINATED", "last_update": "2024-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03178201", "title": "TGR1202 in Relapsed and Refractory Follicular Lymphoma", "status": "TERMINATED", "last_update": "2021-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03269669", "title": "Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03314922", "title": "A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)", "status": "COMPLETED", "last_update": "2023-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03364231", "title": "Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2023-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03424122", "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)", "status": "COMPLETED", "last_update": "2025-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03768505", "title": "Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)", "status": "TERMINATED", "last_update": "2024-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03789240", "title": "Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03828448", "title": "Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Na\u00efve Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03884998", "title": "Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03886649", "title": "Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.", "status": "TERMINATED", "last_update": "2022-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03890289", "title": "Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma", "status": "TERMINATED", "last_update": "2024-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03892044", "title": "Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma", "status": "COMPLETED", "last_update": "2024-05-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03919175", "title": "Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma", "status": "TERMINATED", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04156828", "title": "Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-06-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04282018", "title": "Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab", "status": "COMPLETED", "last_update": "2026-02-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379167", "title": "A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma", "status": "UNKNOWN", "last_update": "2020-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04431089", "title": "Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma", "status": "UNKNOWN", "last_update": "2021-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04508647", "title": "Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma", "status": "COMPLETED", "last_update": "2024-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04635683", "title": "Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma", "status": "WITHDRAWN", "last_update": "2022-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04699461", "title": "Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04707079", "title": "A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma", "status": "UNKNOWN", "last_update": "2021-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04745832", "title": "Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)", "status": "TERMINATED", "last_update": "2024-11-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04750941", "title": "Study of Copanlisib and Ketogenic Diet", "status": "TERMINATED", "last_update": "2025-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04836832", "title": "Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma", "status": "WITHDRAWN", "last_update": "2022-06-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04849351", "title": "Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma", "status": "COMPLETED", "last_update": "2025-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05073250", "title": "IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.", "status": "UNKNOWN", "last_update": "2023-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05152459", "title": "Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma", "status": "WITHDRAWN", "last_update": "2023-05-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05387616", "title": "A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden", "status": "UNKNOWN", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05604417", "title": "Zandelisib + Tazemetostat in R/R Follicular Lymphoma", "status": "WITHDRAWN", "last_update": "2023-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "PI3K", "copanlisib", "idelalisib", "duvelisib", "umbralisib", "zandelisib" ] }, "CD3": { "n": 57, "n_observational": 4, "n_active": 39, "n_withdrawn": 3, "trials": [ { "nct": "NCT04186520", "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies", "status": "RECRUITING", "last_update": "2026-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04889716", "title": "CAR-T Followed by Bispecific Antibodies", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05633615", "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma", "status": "RECRUITING", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05672251", "title": "Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05783609", "title": "Epcoritamab and Rituximab for First-line Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05848765", "title": "Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy", "status": "RECRUITING", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06091254", "title": "A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06149286", "title": "A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06287398", "title": "Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL", "status": "RECRUITING", "last_update": "2024-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06337318", "title": "Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06442475", "title": "Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06453044", "title": "Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06510361", "title": "Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06533579", "title": "Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06536049", "title": "Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06549595", "title": "A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06563596", "title": "Epco, Zanu, Ritux for R/R FL or MZL", "status": "RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06784726", "title": "Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06806033", "title": "Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06854159", "title": "Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy", "status": "RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06905509", "title": "Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma", "status": "RECRUITING", "last_update": "2026-06-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06948786", "title": "Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07101328", "title": "A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07128641", "title": "Odronextamab in Low Tumor Volume Advanced FL", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07191249", "title": "Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma .", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07548697", "title": "A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-04-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005852", "title": "Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant", "status": "TERMINATED", "last_update": "2012-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006252", "title": "Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma", "status": "COMPLETED", "last_update": "2016-07-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00014560", "title": "Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2018-05-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00161187", "title": "Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor", "status": "COMPLETED", "last_update": "2015-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00244946", "title": "Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2015-03-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00521261", "title": "Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "WITHDRAWN", "last_update": "2014-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00816413", "title": "Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer", "status": "WITHDRAWN", "last_update": "2023-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00889408", "title": "DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma", "status": "COMPLETED", "last_update": "2017-12-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01163201", "title": "T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies", "status": "WITHDRAWN", "last_update": "2017-12-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02290951", "title": "Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies", "status": "COMPLETED", "last_update": "2025-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02454270", "title": "A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies", "status": "TERMINATED", "last_update": "2018-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02568553", "title": "Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2025-11-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03570892", "title": "Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2026-06-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03888105", "title": "A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04007029", "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04542824", "title": "Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04594642", "title": "A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04663347", "title": "Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04763083", "title": "First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies", "status": "UNKNOWN", "last_update": "2023-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04806035", "title": "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2024-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05169658", "title": "Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05410418", "title": "Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05464329", "title": "Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05660967", "title": "Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma", "status": "TERMINATED", "last_update": "2026-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05783596", "title": "Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06097364", "title": "A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06112847", "title": "Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06575686", "title": "Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma", "status": "SUSPENDED", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07168291", "title": "Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-17", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07187960", "title": "Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07714421", "title": "Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 9, "n_observational": 0, "n_active": 7, "n_withdrawn": 1, "trials": [ { "nct": "NCT04186520", "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies", "status": "RECRUITING", "last_update": "2026-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04889716", "title": "CAR-T Followed by Bispecific Antibodies", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05633615", "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma", "status": "RECRUITING", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06784726", "title": "Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06854159", "title": "Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy", "status": "RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00161187", "title": "Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor", "status": "COMPLETED", "last_update": "2015-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00521261", "title": "Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "WITHDRAWN", "last_update": "2014-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04007029", "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07168291", "title": "Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-17", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "CD3", "bispecific" ] } }, "by_drug": { "ACALABRUTINIB": { "n": 10, "n_observational": 0, "n_active": 6, "n_withdrawn": 1, "trials": [ { "nct": "NCT04883437", "title": "Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas", "status": "RECRUITING", "last_update": "2026-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02180711", "title": "Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02328014", "title": "Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies", "status": "COMPLETED", "last_update": "2025-12-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02362035", "title": "ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies", "status": "COMPLETED", "last_update": "2026-05-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03162536", "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04257578", "title": "Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04404088", "title": "Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04836832", "title": "Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma", "status": "WITHDRAWN", "last_update": "2022-06-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05583149", "title": "Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AXICABTAGENE CILOLEUCEL": { "n": 14, "n_observational": 2, "n_active": 8, "n_withdrawn": 0, "trials": [ { "nct": "NCT05077527", "title": "Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05633615", "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma", "status": "RECRUITING", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06043323", "title": "A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06550141", "title": "Emapalumab Prevention of CAR-T Cell Associated Toxicities", "status": "RECRUITING", "last_update": "2025-11-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06826118", "title": "Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma", "status": "RECRUITING", "last_update": "2025-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07042438", "title": "Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02348216", "title": "Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2024-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03105336", "title": "A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2025-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04205838", "title": "Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma", "status": "TERMINATED", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04257578", "title": "Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04432506", "title": "Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma", "status": "COMPLETED", "last_update": "2025-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04855253", "title": "Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL", "status": "SUSPENDED", "last_update": "2026-01-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05075603", "title": "Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy", "status": "COMPLETED", "last_update": "2026-08-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05371093", "title": "Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "BL22": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT00024115", "title": "BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia", "status": "WITHDRAWN", "last_update": "2015-04-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00126646", "title": "BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2010-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "BLINATUMOMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02568553", "title": "Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2025-11-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "BREXUCABTAGENE AUTOLEUCEL": { "n": 0, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "BUPARLISIB": { "n": 4, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01693614", "title": "Safety and Efficacy of BKM120 in Relapsed and Refractory NHL", "status": "COMPLETED", "last_update": "2018-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01719250", "title": "Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2018-10-09", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02049541", "title": "Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02756247", "title": "A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma", "status": "COMPLETED", "last_update": "2022-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "COPANLISIB": { "n": 6, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT03789240", "title": "Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03884998", "title": "Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03886649", "title": "Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.", "status": "TERMINATED", "last_update": "2022-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04156828", "title": "Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-06-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04750941", "title": "Study of Copanlisib and Ketogenic Diet", "status": "TERMINATED", "last_update": "2025-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05387616", "title": "A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden", "status": "UNKNOWN", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DENINTUZUMAB MAFODOTIN": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01786135", "title": "A Safety Study of SGN-CD19A for B-Cell Lymphoma", "status": "COMPLETED", "last_update": "2017-10-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02592876", "title": "Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma", "status": "TERMINATED", "last_update": "2019-05-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02855359", "title": "Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma", "status": "TERMINATED", "last_update": "2019-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DUVELISIB": { "n": 11, "n_observational": 2, "n_active": 3, "n_withdrawn": 3, "trials": [ { "nct": "NCT04803201", "title": "Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06522737", "title": "A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07293403", "title": "Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02204982", "title": "Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-09-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02391545", "title": "A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)", "status": "TERMINATED", "last_update": "2023-09-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02576275", "title": "A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)", "status": "WITHDRAWN", "last_update": "2021-03-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02605694", "title": "Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)", "status": "WITHDRAWN", "last_update": "2021-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03892044", "title": "Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma", "status": "COMPLETED", "last_update": "2024-05-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379167", "title": "A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma", "status": "UNKNOWN", "last_update": "2020-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04707079", "title": "A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma", "status": "UNKNOWN", "last_update": "2021-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04836832", "title": "Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma", "status": "WITHDRAWN", "last_update": "2022-06-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "EPCORITAMAB": { "n": 22, "n_observational": 2, "n_active": 18, "n_withdrawn": 1, "trials": [ { "nct": "NCT05783609", "title": "Epcoritamab and Rituximab for First-line Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05848765", "title": "Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy", "status": "RECRUITING", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06287398", "title": "Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL", "status": "RECRUITING", "last_update": "2024-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06510361", "title": "Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06536049", "title": "Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06563596", "title": "Epco, Zanu, Ritux for R/R FL or MZL", "status": "RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06905509", "title": "Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma", "status": "RECRUITING", "last_update": "2026-06-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07197307", "title": "Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04358458", "title": "First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas", "status": "TERMINATED", "last_update": "2024-10-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04542824", "title": "Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04628494", "title": "A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04663347", "title": "Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05409066", "title": "Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05451810", "title": "A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05660967", "title": "Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma", "status": "TERMINATED", "last_update": "2026-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06112847", "title": "Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06191744", "title": "Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06575686", "title": "Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma", "status": "SUSPENDED", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07030699", "title": "A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma", "status": "WITHDRAWN", "last_update": "2026-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07714421", "title": "Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07783594", "title": "Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07814001", "title": "Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "EPRATUZUMAB": { "n": 9, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00003337", "title": "Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma", "status": "UNKNOWN", "last_update": "2021-08-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003338", "title": "Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma", "status": "UNKNOWN", "last_update": "2021-08-16", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004084", "title": "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia", "status": "COMPLETED", "last_update": "2011-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004086", "title": "Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer", "status": "UNKNOWN", "last_update": "2009-06-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004107", "title": "Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia", "status": "COMPLETED", "last_update": "2011-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00022685", "title": "Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma", "status": "UNKNOWN", "last_update": "2013-12-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00398372", "title": "Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment", "status": "COMPLETED", "last_update": "2011-06-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00553501", "title": "Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2016-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01147393", "title": "Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma", "status": "TERMINATED", "last_update": "2018-02-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "GLOFITAMAB": { "n": 3, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT04889716", "title": "CAR-T Followed by Bispecific Antibodies", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06806033", "title": "Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05783596", "title": "Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "GSK2816126": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02082977", "title": "A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma", "status": "TERMINATED", "last_update": "2020-02-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "IBRUTINIB": { "n": 38, "n_observational": 0, "n_active": 10, "n_withdrawn": 1, "trials": [ { "nct": "NCT01804686", "title": "A Long-term Extension Study of PCI-32765 (Ibrutinib)", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06536049", "title": "Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00849654", "title": "Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma", "status": "COMPLETED", "last_update": "2013-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01109069", "title": "Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2020-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01479842", "title": "Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01569750", "title": "A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2017-08-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01779791", "title": "A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma", "status": "COMPLETED", "last_update": "2017-07-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01829568", "title": "Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01849263", "title": "Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01955499", "title": "Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01974440", "title": "A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2025-05-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01980654", "title": "Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma", "status": "COMPLETED", "last_update": "2019-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02109224", "title": "Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection", "status": "TERMINATED", "last_update": "2015-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02332980", "title": "Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas", "status": "COMPLETED", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02381080", "title": "Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy", "status": "COMPLETED", "last_update": "2017-06-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02401048", "title": "A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas", "status": "COMPLETED", "last_update": "2019-06-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02451111", "title": "Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma", "status": "TERMINATED", "last_update": "2024-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02532257", "title": "Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma", "status": "COMPLETED", "last_update": "2024-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02689869", "title": "Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma", "status": "UNKNOWN", "last_update": "2021-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02733042", "title": "A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2023-11-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02743546", "title": "Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma", "status": "WITHDRAWN", "last_update": "2025-02-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02756247", "title": "A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma", "status": "COMPLETED", "last_update": "2022-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02869633", "title": "Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant", "status": "COMPLETED", "last_update": "2023-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02927964", "title": "TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma", "status": "COMPLETED", "last_update": "2024-10-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02947347", "title": "Study of Ibrutinib and Rituximab in Treatment Na\u00efve Follicular Lymphoma", "status": "COMPLETED", "last_update": "2026-03-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02950220", "title": "Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2019-07-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02956382", "title": "Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma", "status": "COMPLETED", "last_update": "2025-07-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02966730", "title": "Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy", "status": "TERMINATED", "last_update": "2025-05-13", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02991638", "title": "Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers", "status": "UNKNOWN", "last_update": "2018-04-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03162536", "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03198026", "title": "Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03310619", "title": "A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies", "status": "COMPLETED", "last_update": "2024-04-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03424122", "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)", "status": "COMPLETED", "last_update": "2025-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03440567", "title": "Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma", "status": "COMPLETED", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03479268", "title": "Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03570892", "title": "Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2026-06-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04450173", "title": "Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "IDELALISIB": { "n": 16, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01282424", "title": "Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas", "status": "COMPLETED", "last_update": "2019-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01306643", "title": "Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma", "status": "COMPLETED", "last_update": "2018-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01644799", "title": "Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma", "status": "COMPLETED", "last_update": "2026-06-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01732913", "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas", "status": "TERMINATED", "last_update": "2018-11-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01732926", "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas", "status": "TERMINATED", "last_update": "2018-11-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02242045", "title": "Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)", "status": "COMPLETED", "last_update": "2021-03-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02258529", "title": "Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2019-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02332980", "title": "Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas", "status": "COMPLETED", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02536300", "title": "Dose Optimization Study of Idelalisib in Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02603445", "title": "Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL", "status": "COMPLETED", "last_update": "2020-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03133221", "title": "1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2025-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03151057", "title": "Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies", "status": "TERMINATED", "last_update": "2024-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03890289", "title": "Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma", "status": "TERMINATED", "last_update": "2024-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04379167", "title": "A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma", "status": "UNKNOWN", "last_update": "2020-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04699461", "title": "Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "INOTUZUMAB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00299494", "title": "Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)", "status": "COMPLETED", "last_update": "2018-03-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00562965", "title": "Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)", "status": "TERMINATED", "last_update": "2018-01-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "INOTUZUMAB OZOGAMICIN": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00299494", "title": "Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)", "status": "COMPLETED", "last_update": "2018-03-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00562965", "title": "Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)", "status": "TERMINATED", "last_update": "2018-01-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "LFB-R603": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 2, "trials": [ { "nct": "NCT04635683", "title": "Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma", "status": "WITHDRAWN", "last_update": "2022-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04806035", "title": "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2024-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05152459", "title": "Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma", "status": "WITHDRAWN", "last_update": "2023-05-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LISOCABTAGENE MARALEUCEL": { "n": 10, "n_observational": 2, "n_active": 4, "n_withdrawn": 1, "trials": [ { "nct": "NCT05633615", "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma", "status": "RECRUITING", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02631044", "title": "Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)", "status": "COMPLETED", "last_update": "2024-06-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03484702", "title": "Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2024-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04855253", "title": "Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL", "status": "SUSPENDED", "last_update": "2026-01-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05075603", "title": "Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy", "status": "COMPLETED", "last_update": "2026-08-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05359211", "title": "NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05583149", "title": "Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05621096", "title": "Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06313996", "title": "A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma", "status": "WITHDRAWN", "last_update": "2026-03-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07098364", "title": "ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma", "status": "SUSPENDED", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LONCASTUXIMAB TESIRINE": { "n": 9, "n_observational": 0, "n_active": 3, "n_withdrawn": 1, "trials": [ { "nct": "NCT04998669", "title": "Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05672251", "title": "Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07197307", "title": "Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02669017", "title": "Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)", "status": "COMPLETED", "last_update": "2021-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03685344", "title": "Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma", "status": "TERMINATED", "last_update": "2021-10-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04082936", "title": "A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2024-07-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04699461", "title": "Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05228249", "title": "Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma", "status": "WITHDRAWN", "last_update": "2023-01-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05453396", "title": "Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies", "status": "TERMINATED", "last_update": "2026-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "MONO-DGA-RFB4": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00007956", "title": "Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma", "status": "COMPLETED", "last_update": "2015-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "MOSUNETUZUMAB": { "n": 23, "n_observational": 1, "n_active": 21, "n_withdrawn": 0, "trials": [ { "nct": "NCT04792502", "title": "Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04889716", "title": "CAR-T Followed by Bispecific Antibodies", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05389293", "title": "A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05633615", "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma", "status": "RECRUITING", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05672251", "title": "Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05849857", "title": "Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries", "status": "RECRUITING", "last_update": "2023-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06284122", "title": "Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5", "status": "RECRUITING", "last_update": "2026-06-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06337318", "title": "Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06442475", "title": "Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06453044", "title": "Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06948786", "title": "Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07191249", "title": "Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma .", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07555470", "title": "Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04246086", "title": "A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04712097", "title": "A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05169658", "title": "Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05315713", "title": "An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2024-10-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05410418", "title": "Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05412290", "title": "Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05464329", "title": "Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05994235", "title": "Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06492837", "title": "Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07031700", "title": "A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NAVITOCLAX": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00406809", "title": "A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2021-08-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "OBATOCLAX": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT00427856", "title": "Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)", "status": "COMPLETED", "last_update": "2016-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00538187", "title": "Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2015-12-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01238146", "title": "Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma", "status": "WITHDRAWN", "last_update": "2013-06-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "OBINUTUZUMAB": { "n": 67, "n_observational": 5, "n_active": 28, "n_withdrawn": 1, "trials": [ { "nct": "NCT02393157", "title": "Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL", "status": "RECRUITING", "last_update": "2025-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04883437", "title": "Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas", "status": "RECRUITING", "last_update": "2026-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04889716", "title": "CAR-T Followed by Bispecific Antibodies", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05045664", "title": "Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody", "status": "RECRUITING", "last_update": "2026-04-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05848765", "title": "Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy", "status": "RECRUITING", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05929222", "title": "Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06108232", "title": "Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06284122", "title": "Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5", "status": "RECRUITING", "last_update": "2026-06-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06553352", "title": "Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma", "status": "RECRUITING", "last_update": "2024-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06806033", "title": "Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06959732", "title": "Zanubrutinib Combined With G-CVP in Previously Untreated FL", "status": "RECRUITING", "last_update": "2025-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07126678", "title": "Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Na\u00efve Advanced Stage Follicular Lymphoma", "status": "RECRUITING", "last_update": "2025-08-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07299149", "title": "Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00825149", "title": "A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2016-11-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01059630", "title": "A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)", "status": "COMPLETED", "last_update": "2020-01-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01582776", "title": "Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma", "status": "COMPLETED", "last_update": "2023-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01680991", "title": "A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease", "status": "COMPLETED", "last_update": "2016-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01691898", "title": "A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)", "status": "COMPLETED", "last_update": "2020-02-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01995669", "title": "Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2025-06-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02220842", "title": "A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma", "status": "COMPLETED", "last_update": "2020-01-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02257567", "title": "A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma", "status": "COMPLETED", "last_update": "2022-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02391545", "title": "A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)", "status": "TERMINATED", "last_update": "2023-09-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02499003", "title": "GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma", "status": "COMPLETED", "last_update": "2022-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02596971", "title": "A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)", "status": "COMPLETED", "last_update": "2021-05-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02600897", "title": "A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "status": "COMPLETED", "last_update": "2023-12-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02611323", "title": "A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)", "status": "COMPLETED", "last_update": "2023-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02624986", "title": "A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants", "status": "TERMINATED", "last_update": "2020-05-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02631577", "title": "A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma", "status": "COMPLETED", "last_update": "2022-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02689869", "title": "Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma", "status": "UNKNOWN", "last_update": "2021-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02729896", "title": "A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "status": "COMPLETED", "last_update": "2020-12-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02871219", "title": "Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma", "status": "COMPLETED", "last_update": "2025-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02877550", "title": "Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients", "status": "COMPLETED", "last_update": "2022-06-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02992522", "title": "Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03010358", "title": "Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2023-08-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03039114", "title": "Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)", "status": "COMPLETED", "last_update": "2025-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03113422", "title": "Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy", "status": "COMPLETED", "last_update": "2025-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03135262", "title": "A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)", "status": "TERMINATED", "last_update": "2021-12-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03198026", "title": "Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03269669", "title": "Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03276468", "title": "Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas", "status": "COMPLETED", "last_update": "2023-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03332017", "title": "A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma", "status": "COMPLETED", "last_update": "2026-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03341520", "title": "Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma", "status": "COMPLETED", "last_update": "2026-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03401853", "title": "Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma", "status": "TERMINATED", "last_update": "2025-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03492775", "title": "First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients \u2265 60 Years", "status": "COMPLETED", "last_update": "2023-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03817853", "title": "An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma", "status": "COMPLETED", "last_update": "2024-04-04", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03890289", "title": "Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma", "status": "TERMINATED", "last_update": "2024-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03980171", "title": "Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Na\u00efve Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04450173", "title": "Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04578600", "title": "CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma", "status": "COMPLETED", "last_update": "2025-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04599634", "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies", "status": "COMPLETED", "last_update": "2025-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04722601", "title": "A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma", "status": "TERMINATED", "last_update": "2024-05-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04796922", "title": "To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)", "status": "WITHDRAWN", "last_update": "2022-07-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04918940", "title": "Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma", "status": "COMPLETED", "last_update": "2022-12-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04934930", "title": "Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status", "status": "UNKNOWN", "last_update": "2021-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04962126", "title": "Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05058404", "title": "Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05100862", "title": "A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05169658", "title": "Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05387616", "title": "A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden", "status": "UNKNOWN", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05653271", "title": "ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies", "status": "COMPLETED", "last_update": "2026-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05783596", "title": "Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06191744", "title": "Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06474481", "title": "Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06549335", "title": "Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06918015", "title": "Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06961500", "title": "Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07719855", "title": "A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "OBLIMERSEN": { "n": 4, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00054639", "title": "Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2014-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00060112", "title": "Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma", "status": "TERMINATED", "last_update": "2013-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00086944", "title": "Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2013-01-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00301795", "title": "Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2013-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "OCARATUZUMAB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00003874", "title": "Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia", "status": "COMPLETED", "last_update": "2011-11-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00354926", "title": "Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2016-01-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "OCRELIZUMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02723071", "title": "A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)", "status": "COMPLETED", "last_update": "2016-03-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ODRONEXTAMAB": { "n": 8, "n_observational": 3, "n_active": 7, "n_withdrawn": 0, "trials": [ { "nct": "NCT06091254", "title": "A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06149286", "title": "A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06784726", "title": "Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06854159", "title": "Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy", "status": "RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07128641", "title": "Odronextamab in Low Tumor Volume Advanced FL", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02290951", "title": "Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies", "status": "COMPLETED", "last_update": "2025-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03888105", "title": "A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06097364", "title": "A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "OFATUMUMAB": { "n": 13, "n_observational": 0, "n_active": 0, "n_withdrawn": 2, "trials": [ { "nct": "NCT00092274", "title": "Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin\u00b4s Follicular Lymphoma", "status": "WITHDRAWN", "last_update": "2015-04-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00394836", "title": "HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab", "status": "COMPLETED", "last_update": "2014-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00494780", "title": "Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients", "status": "COMPLETED", "last_update": "2014-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00742144", "title": "Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2017-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00823719", "title": "Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)", "status": "COMPLETED", "last_update": "2013-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01077518", "title": "Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy", "status": "TERMINATED", "last_update": "2020-03-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01119794", "title": "Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab", "status": "TERMINATED", "last_update": "2015-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01190449", "title": "Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2021-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01239394", "title": "Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma", "status": "COMPLETED", "last_update": "2017-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01263418", "title": "Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas", "status": "WITHDRAWN", "last_update": "2015-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01286272", "title": "Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2025-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01397591", "title": "Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma", "status": "TERMINATED", "last_update": "2014-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02710643", "title": "\"MIRO\" Molecularly Oriented Immuno-radio-therapy", "status": "COMPLETED", "last_update": "2022-06-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ORELABRUTINIB": { "n": 3, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT04989621", "title": "Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)", "status": "RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07585747", "title": "A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07719855", "title": "A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "PARSACLISIB": { "n": 9, "n_observational": 0, "n_active": 1, "n_withdrawn": 2, "trials": [ { "nct": "NCT03039114", "title": "Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)", "status": "COMPLETED", "last_update": "2025-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126019", "title": "A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma", "status": "COMPLETED", "last_update": "2025-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03314922", "title": "A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)", "status": "COMPLETED", "last_update": "2023-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03424122", "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)", "status": "COMPLETED", "last_update": "2025-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04298879", "title": "IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma", "status": "COMPLETED", "last_update": "2024-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04323956", "title": "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04434937", "title": "Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)", "status": "COMPLETED", "last_update": "2024-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04796922", "title": "To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)", "status": "WITHDRAWN", "last_update": "2022-07-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05867030", "title": "Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma", "status": "WITHDRAWN", "last_update": "2023-10-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "PINATUZUMAB VEDOTIN": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01691898", "title": "A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)", "status": "COMPLETED", "last_update": "2020-02-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PIRTOBRUTINIB": { "n": 4, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT05602363", "title": "AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2025-12-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05990465", "title": "LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06948786", "title": "Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "POLATUZUMAB VEDOTIN": { "n": 15, "n_observational": 0, "n_active": 8, "n_withdrawn": 0, "trials": [ { "nct": "NCT04491370", "title": "Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04844866", "title": "Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients", "status": "RECRUITING", "last_update": "2026-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05633615", "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma", "status": "RECRUITING", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06453044", "title": "Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01691898", "title": "A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)", "status": "COMPLETED", "last_update": "2020-02-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02257567", "title": "A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma", "status": "COMPLETED", "last_update": "2022-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02600897", "title": "A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "status": "COMPLETED", "last_update": "2023-12-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02611323", "title": "A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)", "status": "COMPLETED", "last_update": "2023-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02729896", "title": "A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "status": "COMPLETED", "last_update": "2020-12-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04323956", "title": "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04659044", "title": "Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma", "status": "TERMINATED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05169658", "title": "Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05410418", "title": "Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05455697", "title": "Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07714421", "title": "Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "RITUXIMAB": { "n": 186, "n_observational": 14, "n_active": 33, "n_withdrawn": 10, "trials": [ { "nct": "NCT04834024", "title": "MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma", "status": "RECRUITING", "last_update": "2024-11-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04844866", "title": "Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients", "status": "RECRUITING", "last_update": "2026-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06091254", "title": "A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06287398", "title": "Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL", "status": "RECRUITING", "last_update": "2024-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06350318", "title": "Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas", "status": "RECRUITING", "last_update": "2026-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06549595", "title": "A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06563596", "title": "Epco, Zanu, Ritux for R/R FL or MZL", "status": "RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06792825", "title": "HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06905509", "title": "Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma", "status": "RECRUITING", "last_update": "2026-06-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07226843", "title": "A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07418190", "title": "Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR\u00b2) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07634471", "title": "A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002663", "title": "Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies", "status": "COMPLETED", "last_update": "2023-02-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003356", "title": "Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma", "status": "COMPLETED", "last_update": "2013-10-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003397", "title": "Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2019-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003849", "title": "Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease", "status": "COMPLETED", "last_update": "2016-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003963", "title": "Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2020-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004179", "title": "Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2021-02-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005601", "title": "Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2016-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006721", "title": "S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2026-03-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00007852", "title": "Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2023-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00012051", "title": "Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2013-08-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00017381", "title": "Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2013-01-09", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00022971", "title": "Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2019-12-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00052936", "title": "Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2021-05-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00058227", "title": "Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma", "status": "COMPLETED", "last_update": "2013-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00060671", "title": "Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2015-01-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00062296", "title": "Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00069966", "title": "Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse", "status": "UNKNOWN", "last_update": "2009-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00071955", "title": "Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2013-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00072514", "title": "Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2017-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00078598", "title": "A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma", "status": "UNKNOWN", "last_update": "2005-11-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00080925", "title": "T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies", "status": "COMPLETED", "last_update": "2012-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00089115", "title": "Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2013-08-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00110006", "title": "Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma", "status": "WITHDRAWN", "last_update": "2010-06-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00110149", "title": "Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2017-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00117975", "title": "Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2016-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00147121", "title": "Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)", "status": "COMPLETED", "last_update": "2016-09-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00168740", "title": "Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)", "status": "COMPLETED", "last_update": "2005-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00169208", "title": "Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2019-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00176475", "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease", "status": "TERMINATED", "last_update": "2013-09-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00182650", "title": "Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2009-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00183976", "title": "Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas", "status": "TERMINATED", "last_update": "2014-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00193440", "title": "Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2010-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00238238", "title": "Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab", "status": "COMPLETED", "last_update": "2017-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00244946", "title": "Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2015-03-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00258336", "title": "Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma", "status": "UNKNOWN", "last_update": "2014-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00265928", "title": "Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2008-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00288067", "title": "Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2014-10-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00290511", "title": "Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma", "status": "COMPLETED", "last_update": "2022-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00290667", "title": "Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma", "status": "COMPLETED", "last_update": "2021-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00295932", "title": "Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2018-11-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00299494", "title": "Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)", "status": "COMPLETED", "last_update": "2018-03-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00312845", "title": "Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2012-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00317096", "title": "FCM Versus R-FCM Followed by R-Maintenance or Observation Only", "status": "UNKNOWN", "last_update": "2021-05-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00334438", "title": "Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2016-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00363636", "title": "A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)", "status": "TERMINATED", "last_update": "2015-10-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00366275", "title": "Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma", "status": "COMPLETED", "last_update": "2012-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00384150", "title": "Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)", "status": "TERMINATED", "last_update": "2015-11-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00387023", "title": "Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma", "status": "COMPLETED", "last_update": "2013-11-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00394836", "title": "HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab", "status": "COMPLETED", "last_update": "2014-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00398372", "title": "Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment", "status": "COMPLETED", "last_update": "2011-06-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00400478", "title": "A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13", "status": "COMPLETED", "last_update": "2016-05-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00400764", "title": "A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas", "status": "TERMINATED", "last_update": "2011-11-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00411086", "title": "Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma", "status": "COMPLETED", "last_update": "2017-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00428142", "title": "Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00430352", "title": "MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.", "status": "COMPLETED", "last_update": "2017-08-14", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00435955", "title": "Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma", "status": "UNKNOWN", "last_update": "2007-02-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00452127", "title": "A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2013-01-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00460109", "title": "Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2017-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00496873", "title": "Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan", "status": "COMPLETED", "last_update": "2023-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00509379", "title": "Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma", "status": "COMPLETED", "last_update": "2011-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00510887", "title": "Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma", "status": "TERMINATED", "last_update": "2014-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00536978", "title": "Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2020-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00546377", "title": "Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer", "status": "COMPLETED", "last_update": "2016-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00551239", "title": "Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma", "status": "WITHDRAWN", "last_update": "2020-10-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00553501", "title": "Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2016-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00556699", "title": "A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2014-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00574730", "title": "CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2023-09-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00617929", "title": "Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant", "status": "TERMINATED", "last_update": "2017-12-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00634179", "title": "A Phase I/II Trial of VR-CHOP in Lymphoma Patients", "status": "COMPLETED", "last_update": "2016-10-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00691652", "title": "Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2019-11-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00715208", "title": "Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma", "status": "COMPLETED", "last_update": "2013-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00719472", "title": "A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)", "status": "COMPLETED", "last_update": "2017-05-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00720135", "title": "Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2015-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00772668", "title": "Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL", "status": "TERMINATED", "last_update": "2017-12-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00783367", "title": "Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas", "status": "COMPLETED", "last_update": "2023-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00818961", "title": "Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer", "status": "TERMINATED", "last_update": "2013-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00842114", "title": "Rituximab and CVP Plus Interferon for Follicular Non Hodgkins Lymphoma (NHL)", "status": "COMPLETED", "last_update": "2016-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00859001", "title": "Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy", "status": "COMPLETED", "last_update": "2009-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00880815", "title": "Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant", "status": "COMPLETED", "last_update": "2019-06-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00896519", "title": "GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma", "status": "UNKNOWN", "last_update": "2013-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00904722", "title": "Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma", "status": "COMPLETED", "last_update": "2016-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00912223", "title": "Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)", "status": "COMPLETED", "last_update": "2022-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00968760", "title": "CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies", "status": "COMPLETED", "last_update": "2023-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00987493", "title": "Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma", "status": "COMPLETED", "last_update": "2019-05-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00991211", "title": "Bendamustine Plus Rituximab Versus CHOP Plus Rituximab", "status": "COMPLETED", "last_update": "2024-08-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00992446", "title": "Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2020-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01044745", "title": "Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer", "status": "TERMINATED", "last_update": "2023-09-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01077518", "title": "Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy", "status": "TERMINATED", "last_update": "2020-03-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01116232", "title": "Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation", "status": "TERMINATED", "last_update": "2019-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01124526", "title": "Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma", "status": "COMPLETED", "last_update": "2010-05-17", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01127841", "title": "Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line", "status": "UNKNOWN", "last_update": "2013-08-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01145495", "title": "Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2023-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01186458", "title": "Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2016-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01200758", "title": "A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2018-11-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01210287", "title": "Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP", "status": "UNKNOWN", "last_update": "2014-01-08", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01238146", "title": "Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma", "status": "WITHDRAWN", "last_update": "2013-06-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01275209", "title": "Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma", "status": "COMPLETED", "last_update": "2020-12-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01307592", "title": "Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma", "status": "UNKNOWN", "last_update": "2014-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01307605", "title": "Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01329354", "title": "Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy", "status": "UNKNOWN", "last_update": "2017-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01361191", "title": "Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma", "status": "COMPLETED", "last_update": "2013-10-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01381692", "title": "Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma", "status": "COMPLETED", "last_update": "2021-10-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01419665", "title": "GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)", "status": "COMPLETED", "last_update": "2021-05-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01446562", "title": "Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma", "status": "COMPLETED", "last_update": "2016-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01460602", "title": "Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma", "status": "WITHDRAWN", "last_update": "2020-09-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01473628", "title": "Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01493479", "title": "Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma", "status": "COMPLETED", "last_update": "2019-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01510184", "title": "Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy", "status": "TERMINATED", "last_update": "2021-12-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01560117", "title": "Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma", "status": "COMPLETED", "last_update": "2018-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01569750", "title": "A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2017-08-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01691898", "title": "A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)", "status": "COMPLETED", "last_update": "2020-02-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01796171", "title": "A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2024-06-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01830465", "title": "VELCADE\u00ae Plus Rituximab in Non Hodgkin's Follicular Lymphoma", "status": "COMPLETED", "last_update": "2013-04-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01852435", "title": "R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B", "status": "UNKNOWN", "last_update": "2017-11-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01994382", "title": "Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL", "status": "COMPLETED", "last_update": "2022-04-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02049541", "title": "Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02063685", "title": "Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma", "status": "COMPLETED", "last_update": "2022-06-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02162771", "title": "To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan", "status": "COMPLETED", "last_update": "2020-01-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02168907", "title": "CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2018-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02213263", "title": "A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera\u00ae (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)", "status": "COMPLETED", "last_update": "2019-06-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02257567", "title": "A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma", "status": "COMPLETED", "last_update": "2022-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02258529", "title": "Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma", "status": "TERMINATED", "last_update": "2019-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02260804", "title": "To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02303119", "title": "Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)", "status": "COMPLETED", "last_update": "2023-01-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02320292", "title": "Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma", "status": "TERMINATED", "last_update": "2025-07-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02348216", "title": "Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2024-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02390869", "title": "Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02391545", "title": "A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)", "status": "TERMINATED", "last_update": "2023-09-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02406092", "title": "Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A", "status": "COMPLETED", "last_update": "2024-11-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02423837", "title": "Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma", "status": "UNKNOWN", "last_update": "2015-04-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02446457", "title": "Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02501473", "title": "Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)", "status": "TERMINATED", "last_update": "2020-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02532257", "title": "Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma", "status": "COMPLETED", "last_update": "2024-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02594163", "title": "Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma", "status": "TERMINATED", "last_update": "2018-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02611323", "title": "A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)", "status": "COMPLETED", "last_update": "2023-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02623920", "title": "Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "status": "WITHDRAWN", "last_update": "2017-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02624986", "title": "A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants", "status": "TERMINATED", "last_update": "2020-05-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02657447", "title": "Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)", "status": "WITHDRAWN", "last_update": "2019-01-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02700022", "title": "A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas", "status": "TERMINATED", "last_update": "2017-11-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02855359", "title": "Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma", "status": "TERMINATED", "last_update": "2019-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02889523", "title": "Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03003546", "title": "Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial", "status": "COMPLETED", "last_update": "2023-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03019666", "title": "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL", "status": "COMPLETED", "last_update": "2022-11-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03069248", "title": "Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon", "status": "COMPLETED", "last_update": "2017-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03121677", "title": "Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03321643", "title": "Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03361852", "title": "Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03424122", "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)", "status": "COMPLETED", "last_update": "2025-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03579927", "title": "CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma", "status": "WITHDRAWN", "last_update": "2020-01-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03704714", "title": "Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma", "status": "SUSPENDED", "last_update": "2022-08-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03789240", "title": "Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03806179", "title": "Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL", "status": "COMPLETED", "last_update": "2023-12-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03919175", "title": "Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma", "status": "TERMINATED", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04138875", "title": "A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)", "status": "WITHDRAWN", "last_update": "2022-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04224493", "title": "A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04404088", "title": "Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04447716", "title": "An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04659044", "title": "Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma", "status": "TERMINATED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04680052", "title": "A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04745832", "title": "Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)", "status": "TERMINATED", "last_update": "2024-11-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762160", "title": "SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma", "status": "TERMINATED", "last_update": "2024-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04850495", "title": "Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05100862", "title": "A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05455697", "title": "Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05867030", "title": "Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma", "status": "WITHDRAWN", "last_update": "2023-10-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05888493", "title": "A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06097364", "title": "A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06191744", "title": "Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06313996", "title": "A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma", "status": "WITHDRAWN", "last_update": "2026-03-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07505849", "title": "ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07714421", "title": "Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07731789", "title": "Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07736950", "title": "A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "SPEBRUTINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02031419", "title": "Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma", "status": "TERMINATED", "last_update": "2024-01-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "TAFASITAMAB": { "n": 9, "n_observational": 0, "n_active": 8, "n_withdrawn": 1, "trials": [ { "nct": "NCT05890352", "title": "Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment", "status": "RECRUITING", "last_update": "2025-10-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06792825", "title": "HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07225439", "title": "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04680052", "title": "A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05455697", "title": "Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05821088", "title": "Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07030699", "title": "A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma", "status": "WITHDRAWN", "last_update": "2026-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07585747", "title": "A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07731789", "title": "Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TAZEMETOSTAT": { "n": 20, "n_observational": 2, "n_active": 7, "n_withdrawn": 3, "trials": [ { "nct": "NCT05890352", "title": "Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment", "status": "RECRUITING", "last_update": "2025-10-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01897571", "title": "Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL", "status": "COMPLETED", "last_update": "2024-03-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02220842", "title": "A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma", "status": "COMPLETED", "last_update": "2020-01-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02875548", "title": "A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study", "status": "COMPLETED", "last_update": "2025-11-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02889523", "title": "Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03010982", "title": "Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors", "status": "COMPLETED", "last_update": "2024-03-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03456726", "title": "Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation", "status": "COMPLETED", "last_update": "2022-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04224493", "title": "A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04537715", "title": "Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels", "status": "COMPLETED", "last_update": "2025-02-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762160", "title": "SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma", "status": "TERMINATED", "last_update": "2024-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05152459", "title": "Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma", "status": "WITHDRAWN", "last_update": "2023-05-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05467943", "title": "Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma", "status": "COMPLETED", "last_update": "2025-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05551936", "title": "A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05604417", "title": "Zandelisib + Tazemetostat in R/R Follicular Lymphoma", "status": "WITHDRAWN", "last_update": "2023-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05618366", "title": "Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2026-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05627245", "title": "Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05934838", "title": "A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05994235", "title": "Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06068881", "title": "A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an \"EZH2 Gain-of-function\" Genetic Mutation", "status": "WITHDRAWN", "last_update": "2026-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06575686", "title": "Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma", "status": "SUSPENDED", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TIRABRUTINIB": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT03162536", "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TISAGENLECLEUCEL": { "n": 7, "n_observational": 3, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT05633615", "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma", "status": "RECRUITING", "last_update": "2026-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03568461", "title": "Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma", "status": "COMPLETED", "last_update": "2026-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03570892", "title": "Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2026-06-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03610724", "title": "Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients", "status": "COMPLETED", "last_update": "2024-06-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04855253", "title": "Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL", "status": "SUSPENDED", "last_update": "2026-01-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05075603", "title": "Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy", "status": "COMPLETED", "last_update": "2026-08-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05888493", "title": "A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "TOSITUMOMAB": { "n": 16, "n_observational": 3, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT00003784", "title": "S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2013-01-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004874", "title": "Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2018-01-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006721", "title": "S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2026-03-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00062894", "title": "Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab", "status": "COMPLETED", "last_update": "2007-09-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00073918", "title": "Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2017-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00073931", "title": "Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2015-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00078598", "title": "A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma", "status": "UNKNOWN", "last_update": "2005-11-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00110071", "title": "Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2014-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00268983", "title": "Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR\u00ae Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma", "status": "COMPLETED", "last_update": "2017-01-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00315731", "title": "A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR\u00ae) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2017-07-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00319332", "title": "A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen", "status": "WITHDRAWN", "last_update": "2015-04-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00475332", "title": "Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar", "status": "TERMINATED", "last_update": "2012-02-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00479167", "title": "A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2021-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00770224", "title": "S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2019-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00933335", "title": "Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab", "status": "COMPLETED", "last_update": "2017-01-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01389076", "title": "Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma", "status": "TERMINATED", "last_update": "2017-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TOSITUMOMAB 131I": { "n": 1, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00004874", "title": "Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2018-01-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "UBLITUXIMAB": { "n": 6, "n_observational": 0, "n_active": 0, "n_withdrawn": 2, "trials": [ { "nct": "NCT02793583", "title": "Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma", "status": "TERMINATED", "last_update": "2022-07-21", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03828448", "title": "Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Na\u00efve Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04508647", "title": "Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma", "status": "COMPLETED", "last_update": "2024-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04635683", "title": "Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma", "status": "WITHDRAWN", "last_update": "2022-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04806035", "title": "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "status": "TERMINATED", "last_update": "2024-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05152459", "title": "Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma", "status": "WITHDRAWN", "last_update": "2023-05-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "UMBRALISIB": { "n": 10, "n_observational": 0, "n_active": 1, "n_withdrawn": 2, "trials": [ { "nct": "NCT02793583", "title": "Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma", "status": "TERMINATED", "last_update": "2022-07-21", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03178201", "title": "TGR1202 in Relapsed and Refractory Follicular Lymphoma", "status": "TERMINATED", "last_update": "2021-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03269669", "title": "Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03364231", "title": "Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2023-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03828448", "title": "Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Na\u00efve Follicular Lymphoma", "status": "TERMINATED", "last_update": "2023-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03919175", "title": "Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma", "status": "TERMINATED", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04508647", "title": "Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma", "status": "COMPLETED", "last_update": "2024-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04635683", "title": "Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma", "status": "WITHDRAWN", "last_update": "2022-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05152459", "title": "Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma", "status": "WITHDRAWN", "last_update": "2023-05-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VECABRUTINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03037645", "title": "Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers", "status": "TERMINATED", "last_update": "2020-10-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VELTUZUMAB": { "n": 4, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00546793", "title": "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL", "status": "COMPLETED", "last_update": "2021-08-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00596804", "title": "Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2021-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00989586", "title": "Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2017-02-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01147393", "title": "Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma", "status": "TERMINATED", "last_update": "2018-02-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VENETOCLAX": { "n": 24, "n_observational": 1, "n_active": 6, "n_withdrawn": 0, "trials": [ { "nct": "NCT06471738", "title": "Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02187861", "title": "A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)", "status": "COMPLETED", "last_update": "2019-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02611323", "title": "A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)", "status": "COMPLETED", "last_update": "2023-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02877550", "title": "Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients", "status": "COMPLETED", "last_update": "2022-06-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02956382", "title": "Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma", "status": "COMPLETED", "last_update": "2025-07-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02992522", "title": "Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03113422", "title": "Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy", "status": "COMPLETED", "last_update": "2025-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03135262", "title": "A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)", "status": "TERMINATED", "last_update": "2021-12-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03276468", "title": "Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas", "status": "COMPLETED", "last_update": "2023-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03357627", "title": "A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2023-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03547115", "title": "A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML", "status": "TERMINATED", "last_update": "2026-03-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03552692", "title": "Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma", "status": "TERMINATED", "last_update": "2023-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03583424", "title": "Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2025-05-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03886649", "title": "Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.", "status": "TERMINATED", "last_update": "2022-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03980171", "title": "Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Na\u00efve Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04447716", "title": "An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04450173", "title": "Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04599634", "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies", "status": "COMPLETED", "last_update": "2025-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04659044", "title": "Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma", "status": "TERMINATED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04722601", "title": "A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma", "status": "TERMINATED", "last_update": "2024-05-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05107856", "title": "PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies", "status": "TERMINATED", "last_update": "2024-01-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05618366", "title": "Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2026-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05753501", "title": "Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "VOXTALISIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01403636", "title": "A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia", "status": "COMPLETED", "last_update": "2016-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "YTTRIUM Y 90 EPRATUZUMAB": { "n": 4, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00004084", "title": "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia", "status": "COMPLETED", "last_update": "2011-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004086", "title": "Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer", "status": "UNKNOWN", "last_update": "2009-06-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004107", "title": "Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia", "status": "COMPLETED", "last_update": "2011-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01147393", "title": "Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma", "status": "TERMINATED", "last_update": "2018-02-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01147393", "title": "Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma", "status": "TERMINATED", "last_update": "2018-02-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN": { "n": 35, "n_observational": 2, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT00005592", "title": "Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2015-10-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00012298", "title": "Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2018-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00017381", "title": "Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2013-01-09", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00031642", "title": "Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2023-12-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00033423", "title": "Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2013-12-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00058292", "title": "Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2012-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00110149", "title": "Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2017-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00119392", "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2018-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00185393", "title": "Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy", "status": "COMPLETED", "last_update": "2008-12-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00310128", "title": "Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma", "status": "WITHDRAWN", "last_update": "2016-02-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00334438", "title": "Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma", "status": "COMPLETED", "last_update": "2016-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00354822", "title": "Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.", "status": "TERMINATED", "last_update": "2009-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00372905", "title": "Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma", "status": "TERMINATED", "last_update": "2019-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00387023", "title": "Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma", "status": "COMPLETED", "last_update": "2013-11-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00392691", "title": "Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment", "status": "COMPLETED", "last_update": "2019-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00397800", "title": "Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma", "status": "UNKNOWN", "last_update": "2012-08-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00438880", "title": "Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2016-02-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00493454", "title": "Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas", "status": "TERMINATED", "last_update": "2013-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00562978", "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients", "status": "COMPLETED", "last_update": "2021-06-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00577278", "title": "A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan", "status": "COMPLETED", "last_update": "2024-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00637832", "title": "Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma", "status": "TERMINATED", "last_update": "2022-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00695409", "title": "Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma", "status": "COMPLETED", "last_update": "2018-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00722930", "title": "Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma", "status": "UNKNOWN", "last_update": "2008-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00732498", "title": "Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL", "status": "COMPLETED", "last_update": "2019-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00772655", "title": "Zevalin\u00ae First Line in Follicular Lymphoma", "status": "UNKNOWN", "last_update": "2012-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01130194", "title": "Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma", "status": "COMPLETED", "last_update": "2014-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01234766", "title": "Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma", "status": "COMPLETED", "last_update": "2021-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01446562", "title": "Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma", "status": "COMPLETED", "last_update": "2016-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01493479", "title": "Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma", "status": "COMPLETED", "last_update": "2019-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01510184", "title": "Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy", "status": "TERMINATED", "last_update": "2021-12-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01549886", "title": "Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2021-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01662102", "title": "Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)", "status": "TERMINATED", "last_update": "2021-10-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01827605", "title": "A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)", "status": "COMPLETED", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02063685", "title": "Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma", "status": "COMPLETED", "last_update": "2022-06-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02320292", "title": "Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma", "status": "TERMINATED", "last_update": "2025-07-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "ZANDELISIB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT03768505", "title": "Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)", "status": "TERMINATED", "last_update": "2024-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04745832", "title": "Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)", "status": "TERMINATED", "last_update": "2024-11-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05604417", "title": "Zandelisib + Tazemetostat in R/R Follicular Lymphoma", "status": "WITHDRAWN", "last_update": "2023-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ZANUBRUTINIB": { "n": 26, "n_observational": 2, "n_active": 20, "n_withdrawn": 0, "trials": [ { "nct": "NCT05389293", "title": "A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05890352", "title": "Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment", "status": "RECRUITING", "last_update": "2025-10-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06350318", "title": "Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas", "status": "RECRUITING", "last_update": "2026-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06471738", "title": "Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06553352", "title": "Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma", "status": "RECRUITING", "last_update": "2024-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06563596", "title": "Epco, Zanu, Ritux for R/R FL or MZL", "status": "RECRUITING", "last_update": "2026-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06859008", "title": "Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "status": "RECRUITING", "last_update": "2026-04-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06959732", "title": "Zanubrutinib Combined With G-CVP in Previously Untreated FL", "status": "RECRUITING", "last_update": "2025-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07126678", "title": "Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Na\u00efve Advanced Stage Follicular Lymphoma", "status": "RECRUITING", "last_update": "2025-08-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07299149", "title": "Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07418190", "title": "Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR\u00b2) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02914938", "title": "A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma", "status": "TERMINATED", "last_update": "2023-05-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03162536", "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03332017", "title": "A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma", "status": "COMPLETED", "last_update": "2026-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03520920", "title": "BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)", "status": "COMPLETED", "last_update": "2024-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "status": "COMPLETED", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04172246", "title": "Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies", "status": "COMPLETED", "last_update": "2025-11-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04282018", "title": "Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab", "status": "COMPLETED", "last_update": "2026-02-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04850495", "title": "Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05100862", "title": "A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06474481", "title": "Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06492837", "title": "Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06549335", "title": "Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06918015", "title": "Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07505849", "title": "ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07550855", "title": "Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] } } } }